<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74623</article-id><article-id pub-id-type="doi">10.7554/eLife.74623</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-256595"><name><surname>Gawish</surname><given-names>Riem</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4267-2131</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-258058"><name><surname>Starkl</surname><given-names>Philipp</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7521-129X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258059"><name><surname>Pimenov</surname><given-names>Lisabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258060"><name><surname>Hladik</surname><given-names>Anastasiya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258061"><name><surname>Lakovits</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258062"><name><surname>Oberndorfer</surname><given-names>Felicitas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258064"><name><surname>Cronin</surname><given-names>Shane JF</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52213"><name><surname>Ohradanova-Repic</surname><given-names>Anna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8005-8522</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254463"><name><surname>Wirnsberger</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-258065"><name><surname>Agerer</surname><given-names>Benedikt</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258066"><name><surname>Endler</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258067"><name><surname>Capraz</surname><given-names>Tümay</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254457"><name><surname>Perthold</surname><given-names>Jan W</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33774"><name><surname>Cikes</surname><given-names>Domagoj</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265622"><name><surname>Koglgruber</surname><given-names>Rubina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258068"><name><surname>Hagelkruys</surname><given-names>Astrid</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247849"><name><surname>Montserrat</surname><given-names>Nuria</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-152982"><name><surname>Mirazimi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-219210"><name><surname>Boon</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258070"><name><surname>Stockinger</surname><given-names>Hannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6404-4430</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258071"><name><surname>Bergthaler</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183997"><name><surname>Oostenbrink</surname><given-names>Chris</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4232-2556</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-212735"><name><surname>Penninger</surname><given-names>Josef M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-258072"><name><surname>Knapp</surname><given-names>Sylvia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9016-5244</contrib-id><email>Sylvia.knapp@meduniwien.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution>Institute of Molecular Biotechnology of the Austrian Academy of Sciences</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution>Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff5"><label>5</label><institution>Aperion Biologics</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff6"><label>6</label><institution>CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff7"><label>7</label><institution>Institute of Molecular Modeling and Simulation, Department of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff8"><label>8</label><institution>Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Catalan Institution for Research and Advanced Studies (ICREA)</institution><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff9"><label>9</label><institution>Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff10"><label>10</label><institution>Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology</institution><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff11"><label>11</label><institution>National Veterinary Institute</institution><addr-line><named-content content-type="city">Uppsala</named-content></addr-line><country>Sweden</country></aff><aff id="aff12"><label>12</label><institution>Polpharma Biologics</institution><addr-line><named-content content-type="city">Utrecht</named-content></addr-line><country>Netherlands</country></aff><aff id="aff13"><label>13</label><institution>Department of Medical Genetics, Life Sciences Institute, University of British Columbia</institution><addr-line><named-content content-type="city">Vancouver</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74623</elocation-id><history><date date-type="received" iso-8601-date="2021-10-11"><day>11</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-22"><day>22</day><month>12</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-08-09"><day>09</day><month>08</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.08.09.455606"/></event></pub-history><permissions><copyright-statement>© 2022, Gawish et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Gawish et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74623-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74623-figures-v2.pdf"/><abstract><p>Despite tremendous progress in the understanding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited. We generated maVie16, a mouse-adapted SARS-CoV-2, by serial passaging of a human isolate. In silico modeling revealed how only three Spike mutations of maVie16 enhanced interaction with murine ACE2. maVie16 induced profound pathology in BALB/c and C57BL/6 mice, and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia, and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFNγ and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented mCOVID-19 development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from mCOVID-19, revealing a novel and efficient treatment. Thus, we here present maVie16 as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 in vivo.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mouse-adapted SARS-CoV-2</kwd><kwd>maVie16</kwd><kwd>COVID-19 mouse model</kwd><kwd>cytokine storm</kwd><kwd>recombinant soluble ace2</kwd><kwd>COVID-19 therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>F54-10 and F61-04</award-id><principal-award-recipient><name><surname>Knapp</surname><given-names>Sylvia</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>ZK57-B28</award-id><principal-award-recipient><name><surname>Gawish</surname><given-names>Riem</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P31113-B30</award-id><principal-award-recipient><name><surname>Starkl</surname><given-names>Philipp</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P 34253-B</award-id><principal-award-recipient><name><surname>Ohradanova-Repic</surname><given-names>Anna</given-names></name><name><surname>Stockinger</surname><given-names>Hannes</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>DK W1212</award-id><principal-award-recipient><name><surname>Agerer</surname><given-names>Benedikt</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>Z 271-B19</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001804</institution-id><institution>Canada Research Chairs</institution></institution-wrap></funding-source><award-id>F18-01336</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>F20-02343 and F20-02015</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010767</institution-id><institution>Innovative Medicines Initiative</institution></institution-wrap></funding-source><award-id>101005026</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Only three Spike mutations enable murine SARS-CoV-2 infection, which is still strictly ACE2 dependent and causes a COVID-19-like disease in mice with immunopathology-driven lung damage.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>SARS-CoV-2 was identified as the causative agent of COVID-19 in December 2019 and has since (until August 5, 2021) infected 200 million people and caused 4.3 million confirmed deaths worldwide (<xref ref-type="bibr" rid="bib73">WHO, 2021b</xref>). Upon adaptation to humans, SARS-CoV-2 evolution gave rise to multiple variants including novel SARS-CoV-2 variants of concern (VOCs), characterized by increased transmissibility and/or virulence, or reduced effectiveness of countermeasures such as vaccinations or antibody therapies (<xref ref-type="bibr" rid="bib72">WHO, 2021a</xref>). Clinical symptoms upon SARS-CoV-2 infection show a wide range, from asymptomatic disease to critical illness (<xref ref-type="bibr" rid="bib8">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Paranjpe et al., 2020</xref>). Severe COVID-19 is characterized by progressive respiratory failure, often necessitating hospitalization and mechanical ventilation. Fatal disease is linked to acute respiratory distress syndrome (ARDS), associated with activation of inflammation and thrombosis, often resulting in multiorgan failure (<xref ref-type="bibr" rid="bib8">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Paranjpe et al., 2020</xref>). Epidemiologically, several risk factors, such as age, male sex, diabetes, and obesity, have been found to be associated with the development of severe COVID-19 (<xref ref-type="bibr" rid="bib55">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Zhou et al., 2020</xref>). However, early immunological determinants driving disease severity and outcome of SARS-CoV-2 infection remain elusive.</p><p>While SARS-CoV-2 replicates primarily in nasopharyngeal and type II alveolar epithelial cells in the lower respiratory tract, recent data point towards a broader cellular tropism under certain conditions (<xref ref-type="bibr" rid="bib61">Sungnak et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Ziegler, 2020</xref>). This largely correlates with angiotensin-converting enzyme-2 (ACE2) expression, the entry receptor for SARS-CoV-2 (<xref ref-type="bibr" rid="bib23">Hoffmann et al., 2020</xref>), and TMPRSS2 expression, a protease, which supports viral cell entry (<xref ref-type="bibr" rid="bib23">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Murgolo et al., 2021</xref>). Severe disease seems to be driven by a circuit of T cells and macrophages causing a cytokine release syndrome, immunothrombosis, and resulting tissue damage that resembles macrophage activation syndrome (<xref ref-type="bibr" rid="bib42">Mangalmurti and Hunter, 2020</xref>). As such, IFNγ released by T cells drives the emergence of pathologically activated, hyperinflammatory monocytes and macrophages that produce large amounts of interleukin (IL)-6, TNFα, and IL-1β (<xref ref-type="bibr" rid="bib17">Grant et al., 2021</xref>). Although numerous studies investigated immune responses upon SARS-CoV-2 infection in humans, these studies are largely correlations in hospitalized patients with moderate to severe disease (<xref ref-type="bibr" rid="bib45">Merad et al., 2021</xref>).</p><p>Mechanistic data on early immunological events driving COVID-19 remain sparse due to limited access to human samples and the scarcity of robust small animal models. Notably, mice are resistant to SARS-CoV-2 infection due to phylogenetic differences in ACE2 (<xref ref-type="bibr" rid="bib14">Damas et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Parolin et al., 2021</xref>). To circumvent the missing sensitivity of conventional mice, some groups studying SARS-CoV-2-related immune mechanisms take advantage of KRT18-hACE2 transgenic mice, which express human ACE2 under the epithelial cytokeratin-18 (KRT18) promoter (<xref ref-type="bibr" rid="bib75">Winkler et al., 2020</xref>). However, KRT18-hACE2 mice are overly susceptible as they develop deadly SARS-CoV-2 encephalitis (in addition to pneumonia) in response to low infection doses due to nonphysiological and broad (over)expression of hACE2 (<xref ref-type="bibr" rid="bib31">Kumari et al., 2021</xref>). Recently, four mouse-adapted SARS-CoV-2 strains have been generated by either genetic engineering (<xref ref-type="bibr" rid="bib15">Dinnon et al., 2020</xref>) and/or serial passaging (<xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Leist et al., 2020</xref>). However, while infectivity is achieved with all of these strains, only two (<xref ref-type="bibr" rid="bib25">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Leist et al., 2020</xref>) cause a pathology that mimics human disease, and pathological mechanisms are still poorly understood. Of note, the VOCs Beta/B.1.351 (<xref ref-type="bibr" rid="bib64">Tegally et al., 2020</xref>) and Gamma/P1 <xref ref-type="bibr" rid="bib68">Voloch, 2020</xref> have been recently found to productively replicate in mice without causing pneumonia (<xref ref-type="bibr" rid="bib46">Montagutelli et al., 2021</xref>), indicating that additional mutations might further increase mouse infectivity and pathogenicity.</p><p>In this study, we report the generation of a novel mouse-adapted SARS-CoV-2 virus, <bold>m</bold>ouse-<bold>a</bold>dapted SARS-CoV-2 virus <bold>Vie</bold>nna, passage <bold>16</bold> (maVie16), which causes a disease reminiscent of COVID-19 in humans in two distinct wild-type mouse strains, BALB/c and C57BL/6 mice. We find that the inflammatory cytokines TNF and IFNγ are important drivers of maVie16 pathogenicity. Moreover, we provide the first genetic in vivo proof that ACE2 is the critical SARS-CoV-2 receptor. Finally, therapeutic inhalation of soluble ACE2 completely prevented disease. Our novel mouse maVie16 infection model is thus a useful and relevant model to study immunology and determinants of SARS-CoV-2 infections and COVID-19 in vivo.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generation of the mouse-adapted SARS-CoV-2 strain maVie16</title><p>To generate a virus pathogenic to mice, we infected BALB/c mice with a human SARS-CoV-2 isolate (BetaCoV/Munich/BavPat1/2020; from here on referred to as BavPat1; <xref ref-type="bibr" rid="bib57">Rothe et al., 2020</xref>), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Infectivity was quickly established after the first few passages, as indicated by increasing SARS-CoV-2 genome copies detected in the lungs of infected mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). While the viral load did not further change after passage 3, a progressive loss of body weight of mice infected with later stage passaged SARS-CoV-2 indicated enhanced pathogenicity of the virus (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Weight loss is a sign of disease severity in many rodent models of infection and related to anorexia and/or cachexia (<xref ref-type="bibr" rid="bib3">Baazim et al., 2021</xref>). Mice infected with passage 15 furthermore exhibited a severe drop in body temperature (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), which is the regulatory response of mice to severe inflammation at room temperature (<xref ref-type="bibr" rid="bib16">Garami et al., 2018</xref>). The transcriptional analysis of pulmonary inflammatory genes (including <italic>Il1b</italic>, <italic>Ifng</italic>, <italic>Il6,</italic> and <italic>Tnf</italic>) 3 days after infection with the different passages revealed a progressively increasing inflammatory response (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These results indicate that our serial passaging protocol has allowed us to generate a highly infectious and pathogenic mouse-adapted SARS-CoV-2 variant (isolated from lungs of mice infected with passage 15), which we refer to as maVie16.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Serial pulmonary passaging of SARS-CoV-2 through BALB/c mice leads to mouse adaptation and generation of the mouse-virulent virus maVie16.</title><p>(<bold>A</bold>) Experimental strategy for generation of maVie16. BALB/c mice were intranasally inoculated with BavPat1 (passage 0/P0), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days. Passaging was repeated 15 times. (<bold>B</bold>) Lung tissue virus genome copy numbers (determined by real-time PCR) of mice 3 days after infection with virus of different passages as indicated. (<bold>C</bold>) Body weight (percentage of initial) of mice 3 days after infection. (<bold>D</bold>) Body temperature before and 3 days after infection. (<bold>E</bold>) Lung tissue expression fold change (compared to P0 mean; analyzed by real-time PCR) of indicated genes 3 days after infection. (<bold>B–E</bold>) n = 1–3; (<bold>B, C, E</bold>) symbols represent individual mice; Kruskal–Wallis test (vs. P0) with Dunn’s multiple comparisons test; (<bold>D</bold>) mean ± SD; two-way ANOVA with Sidak test (vs. the respective initial body temperature); *p≤0.05; **p≤0.01; ***p≤0.001; numbers above bars show the actual p-value.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>Genetic evolution of the maVie16 Spike protein</title><p>To elucidate the mechanisms of mouse adaptation of maVie16, we sequenced SARS-CoV-2 genomes at all passages and compared the viral sequences to the original BavPat1 isolate. Despite the substantially increased virulence in mice, we found only a limited number of mutations with high (&gt;0.5) allele frequencies, located in the Spike protein, open reading frame (ORF)1AB, and envelope (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Given the importance of Spike for SARS-CoV-2 infectivity, we were particularly interested in the three de novo mutations within its receptor binding domain (RBD) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Most prominently, we observed the immediate appearance of Q498H after passage 1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which correlated with the early increase in viral load (and hence viral propagation) in infected mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). After passage 12, we detected a glutamine to arginine exchange at position Q493R (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Importantly, mutations at Q493 and Q498 have been also reported in other mouse-adapted SARS-CoV-2 strains (<xref ref-type="bibr" rid="bib15">Dinnon et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Leist et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2020b</xref>), suggesting a critical role in Spike adaptation to the murine ACE2 receptor. With the appearance of Omicron/B.1.1.529, the most recent VOC, Q493, and Q498 mutations were detected in a human SARS-CoV-2 variant for the first time. Mutations in K417 (which appeared around passage 10; <xref ref-type="fig" rid="fig2">Figure 2B</xref>) have also been reported in Omicron/B.1.1.529 and two other human VOCs, that is, Beta/B.1.351 (K417N) (<xref ref-type="bibr" rid="bib64">Tegally et al., 2020</xref>) and Gamma/P1 (K417T) (<xref ref-type="bibr" rid="bib68">Voloch, 2020</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>maVie16 possesses a distinct pattern of mutations and mediates in vivo pathology via angiotensin-converting enzyme-2 (ACE2).</title><p>(<bold>A</bold>) Overview of allele frequencies of mutated amino acids detected in maVie16 by sequencing. Labels on top indicate the associated protein (SGP, Spike glycoprotein; ORF, open reading frame; MGP, membrane glycoprotein). (<bold>B</bold>) Spike protein mutation dynamics. (<bold>C</bold>) Modeling and location of Spike mutations. Spike trimer in cyan blue and green, mACE2 in magenta cartoon representation. Glycans in stick representations. (<bold>D</bold>) Modeling of specific <italic>BavPat1</italic> (upper row) and maVie16 (lower row) amino acid regions in green (respective mutated positions are highlighted in yellow and labeled in green) and their interaction with mouse ACE2 (in magenta; positions of interest are labeled in magenta or black).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Mouse versus human angiotensin-converting enzyme-2 (ACE2) glycosylation and maVie16 in vitro proliferation.</title><p>(<bold>A</bold>) Surface representation of the binding interface of human (gray cartoon) and mouse (magenta cartoon) ACE2, colored according to the electrostatic potential. Red surface corresponds to a negative potential and blue surface to a positive potential. Note the more distinct pattern of negatively charged areas in the mouse ACE2 protein. A bundle of glycan conformations is shown in sticks for the glycans at N53 (blue), N90 (yellow), N322 (black), and N546 (red) in human ACE2 and at N53 (blue), N536 (green), and N546 (red) in mouse ACE2. (<bold>B</bold>) SARS-CoV-2 genome copy numbers in Vero and Caco-2 cells at indicated time points after infection with a multiplicity of infection (MOI) 0.5 of BavPat1 or maVie16.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Structural analyses of mouse and human ACE2 (mACE2 and hACE2, respectively) have shown that the surface of mACE2 consists of more negative charged amino acids than that of hACE2 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib56">Rodrigues et al., 2020</xref>). Indeed, the exchange of two glutamines (Q493 and Q498) to arginine and histidine, respectively, in the maVie16 Spike results in a positive charged surface (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Detailed structural modeling of the BavPat1 versus the maVie16 Spike protein interface with mACE2 revealed that the maVie16 Spike Q498H mutation would strengthen its interaction with mACE2 at amino acid D38, otherwise forming an intramolecular salt bridge with mACE2 H353 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Similarly, the newly introduced arginine at maVie16 Spike position 493 is predicted to efficiently interact with the negatively charged mACE2 amino acid E35, thus further stabilizing the maVie16 Spike/mACE2 interaction by neutralizing the otherwise unpaired negative charge of mACE2 glutamic acid (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Finally, the threonine at Spike position 417 (T417) of maVie16’s is predicted to enhance the interaction with the neutrally charged asparagine at position 30 of mACE2 while the aspartic acid at this position in hACE2 forms a salt bridge with lysine K417 of the original <italic>BavPat1</italic> isolate. Since the observed Spike mutations are distant from putative cleavage sites (<xref ref-type="bibr" rid="bib63">Takeda, 2022</xref>), it is likely that mACE2 affinity is increased without affecting proteolytic processing by proteases such as furin or TMPRSS2 (<xref ref-type="bibr" rid="bib63">Takeda, 2022</xref>). Of note, maVie16 showed similar propagation kinetics in Vero and Caco-2 cells as compared to BavPat1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Thus, while the interaction with mACE2 is enhanced, the infectivity of human cells remained unchanged for maVie16 and both simian and human cells continue to serve as a useful tool for maVie16 propagation and titer determination. Taken together, our data indicate that only three distinct Spike RBD mutations introduced during passaging could substantially enhance interaction with mACE2, without obvious effects on the interaction with hACE2.</p></sec><sec id="s2-3"><title>maVie16 causes severe pneumonia in BALB/c and C57BL/6 mice</title><p>We next performed dose–response experiments of maVie16 infections in BALB/c (B/c) and, as a commonly used mouse strain for genetic engineering, C57BL/6 (B/6) mice and monitored weight and body temperatures over 7 days. In BALB/c mice, maVie16 was highly pathogenic and caused profound weight loss, starting around day 3 post infection (p.i.) at a dose of 4 × 10<sup>3</sup> TCID<sub>50</sub> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), whereas all tested higher doses caused an earlier weight loss (day 2 p.i.) and lethality starting at day 4 p.i. (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Notably, the loss of body weight correlated with hypothermia (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In contrast to BALB/c mice, maVie16 infection did not cause lethality nor significant hypothermia in C57BL/6 animals, albeit 1 × 10<sup>5</sup> (and higher) TCID<sub>50</sub> induced a profound but transient body weight loss of about 15% (<xref ref-type="fig" rid="fig3">Figure 3D–F</xref>). Interestingly, both mouse strains infected with 1 × 10<sup>5</sup> TCID<sub>50</sub> showed similar body weight loss (approximately 15%) at day 3 p.i., but while disease severity further increased in BALB/c animals, C57BL/6 mice recovered. In line with these data, BALB/c animals showed more severe lung pathologies compared to C57BL/6 mice, as revealed by histological analyses of lungs on day 3 (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). While the cumulative histological score revealed no differences between the strains, diffuse alveolar damage, characterized by alveolar collapse and septal thickening, was more pronounced in BALB/c mice (<xref ref-type="fig" rid="fig3">Figure 3I</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Respiratory maVie16 infection causes dose-dependent pathology in BALB/c and C57BL/6 mice.</title><p>(<bold>A–C, G</bold>) BALB/c (B/c) or (<bold>D–F, H</bold>) C57BL/6 (B/6) mice were intranasally inoculated with different doses of maVie16 as indicated and monitored for (<bold>A, D</bold>) body weight, (<bold>B, E</bold>) survival and (<bold>C, F</bold>) body temperature over 7 days; dashed lines in (<bold>A</bold>) and (<bold>C</bold>) indicate trajectories of groups lacking full group size due to death of animals (see <bold>B</bold>). (<bold>G, H</bold>) Lung sections (hematoxylin and eosin stain) from mice 3 days after infection with 10<sup>5</sup> TCID<sub>50</sub> maVie16; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars indicate 100 µm. (<bold>I</bold>) Histological score for analysis of lung sections as described in (<bold>G</bold>) and (<bold>H</bold>); symbols represent individual mice; (<bold>A, C, D, F</bold>) mean ± SD; (<bold>B</bold>) Mantel–Cox test (vs. 4 × 10<sup>3</sup> TCID<sub>50</sub>); **p≤0.01; the number next to the symbol shows the actual p-value.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Disease kinetics of BavPat1-infected KRT18-hACE2 mice.</title><p>(<bold>A–F</bold>) Mice expressing human ACE2 under control of the human <italic>KERATIN-18</italic> promoter (KRT18-hACE2/+) and control animals (<italic>+/+</italic>) were intranasally inoculated with (<bold>A, C, E</bold>) 10<sup>3</sup> or (<bold>B, D, F</bold>) 10<sup>4</sup> TCID<sub>50</sub> of BavPat1 and monitored over 7 days. (<bold>A, B</bold>) Survival; (<bold>C, D</bold>) body weight; (<bold>E, F</bold>) temperature; (<bold>A</bold>–<bold>F</bold>) n = 4–7; (<bold>E, F</bold>) mean ± SD.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To compare our data with a widely used mouse model of COVID-19, we infected KRT18-hACE2 transgenic mice that express human ACE2 under control of the human keratin 18 promoter (<xref ref-type="bibr" rid="bib44">McCray et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Oladunni et al., 2020</xref>) with either 1 × 10<sup>3</sup> or 1 × 10<sup>4</sup> TCID<sub>50</sub> of BavPat1 and monitored the disease course over 7 days. As expected (<xref ref-type="bibr" rid="bib49">Oladunni et al., 2020</xref>), KRT18-hACE2 mice were most sensitive to infection and succumbed to BavPat1 infections (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). However, the disease course was profoundly different to that of maVie16-infected wild-type animals. BavPat1-infected KRT18-hACE2 mice appeared healthy until day 4 p.i. and then progressively lost weight until day 7, accompanied by hypothermia and death (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–F</xref>). Death in KRT18-hACE2 mice most likely results from severe encephalitis due to expression of hACE2 in neurons where ACE2 is normally not expressed (<xref ref-type="bibr" rid="bib22">Hikmet et al., 2020</xref>). These results show that maVie16 causes severe pathology in BALB/c and profound, but transient, disease in C57BL/6 mice, recapitulating critical aspects (such as transient pneumonia and viral clearance) of human COVID-19.</p></sec><sec id="s2-4"><title>Murine anti-SARS-CoV-2 immune responses</title><p>To better understand the pathophysiology of mouse COVID-19 (mCOVID-19), we next profiled immune cell dynamics in blood and lungs of C57BL/6 mice during acute infection and upon recovery. maVie16 (5 × 10<sup>5</sup> TCID<sub>50</sub>) infection caused severe blood leukopenia on day 2 p.i. with a prominent reduction of lymphocytes, monocytes, neutrophils, and NK cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). At the same time, we observed an expansion of peripheral plasmacytoid dendritic cells (pDCs) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), which are important antiviral effector cells capable of efficient and rapid type I IFN production (<xref ref-type="bibr" rid="bib62">Swiecki and Colonna, 2015</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mouse COVID-19 (mCOVID-19) is associated with transient lymphopenia, pulmonary dendritic cell, and T cell infiltration and pneumonia.</title><p>C57BL/6 mice were intranasally infected with PBS ( = group 0) or 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and sacrificed after 2, 5, 7, or 14 days for subsequent analysis. (<bold>A</bold>) Flow cytometry analysis of blood cell populations. (<bold>B</bold>) Density plot representation of blood plasmacytoid dendritic cells (pDCs; identified as live/CD45<sup>+</sup>/CD11c<sup>+</sup>/BST2<sup>+</sup>) analyzed by flow cytometry. (<bold>C</bold>) Flow cytometry analysis of whole lung cell populations (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for gating strategies). (<bold>D</bold>) Lung tissue expression fold change (compared to group 0 mean; analyzed by real-time PCR) of indicated genes from mice at the respective time points after infection. (<bold>A, C, D</bold>): symbols represent individual mice; Kruskal–Wallis test (vs. group 0) with Dunn’s multiple comparisons test; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Flow cytometry gating strategy for lung cells.</title><p>C57BL/6 mice were intranasally infected with PBS ( = group 0) or 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and sacrificed after 2, 5, 7, or 14 days for subsequent analysis. (<bold>A</bold>) Example of the flow cytometry gating strategy for immune cell populations (shown in <xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). The sample is derived from an infected mouse 2 days post infection.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Cellular, transcriptional, and spleen weight kinetics of maVie16-infected C57BL/6 mice.</title><p>C57BL/6 mice were intranasally infected with PBS ( = group 0) or 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and sacrificed after 2, 5, 7, or 14 days for subsequent analysis. (<bold>A</bold>) Flow cytometry analysis of blood cell populations. (<bold>B</bold>) Flow cytometry analysis of whole lung cell populations (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for gating strategies). (<bold>C</bold>) Lung tissue expression fold change (compared to group 0 mean; analyzed by real-time PCR) of indicated genes from mice at the respective time points after infection. (<bold>D</bold>) Spleen weight at indicated time points after infection. (<bold>A–D</bold>) symbols represent individual mice; Kruskal–Wallis test (vs. group 0) with Dunn’s multiple comparisons test; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Infection led to substantial pulmonary infiltration with leukocytes (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), paralleling the development of pneumonia. A closer look at the inflammatory cell composition in the lungs revealed a remarkable infiltration with pDCs on day 2 p.i. (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Conventional dendritic cells (cDCs) transiently accumulated in the lung on day 5 p.i., followed by T helper and cytotoxic T cell infiltration and recruitment of monocytes on day 7 (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). The abundance of other analyzed immune cell populations did not change substantially, and lung neutrophil numbers dropped around day 2 p.i. to return to baseline levels over the remaining disease course (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Surprisingly, pulmonary NK cells, which fulfill important antiviral functions (<xref ref-type="bibr" rid="bib4">Björkström et al., 2021</xref>), did not significantly expand in the lungs of maVie16 infected C57BL6 mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). In line with an early lung pDC accumulation, we found rapid induction of type I IFN-inducible genes, such as <italic>Eif2ak2</italic> (protein kinase R/PKR) and <italic>ifit1</italic>, accompanied by a profound <italic>Il6</italic> response; the expression of <italic>Tnf</italic>, <italic>Il10</italic>, <italic>Il1b,</italic> and <italic>Tgfb</italic> peaked between day 5 and 7 p.i. (<xref ref-type="fig" rid="fig4">Figure 4D</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). The <italic>Ifng</italic> induction reached a maximum on day 7, coinciding with the increased numbers of T cells that are prominent sources of IFNγ (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><p>In C57BL/6 mice infected with maVie16 (5 × 10<sup>5</sup> TCID<sub>50</sub>), lung weights significantly increased by day 5–7 p.i. (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Lung viral titers peaked at day 2 p.i. and then gradually declined (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Immunohistochemical staining for SARS-CoV-2 nucleoprotein on lung slides confirmed the initial presence and subsequent elimination of viral particles (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Histological analyses of lung tissue revealed progressive interstitial and perivascular infiltration and signs of diffuse alveolar damage, such as alveolar collapse and septal thickening, peaking from day 5–7, and resolving by day 14 p.i. (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Interestingly, vasculitis was observed early after infection (day 2) and resolved at later time points (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Moreover, most acute inflammatory parameters (including cytokine genes, innate immune cells, and lung tissue weights) had returned close to baseline at day 14 p.i. (<xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig5">5A–D</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), confirming resolution of inflammation. Onset of adaptive immunity, as indicated by expansion of pulmonary cDCs and T helper cells by day 5s and 7 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), as well as by increased spleen weight on day 7 p.i. (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>), was followed by an efficient humoral immune response, reflected by significantly increased levels of anti-SARS-CoV-2 Spike protein-specific plasma IgG1, IgG2b, and IgA antibodies on day 14 p.i. (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These data show that maVie16 infection causes severe, yet transient, lung inflammation in C57BL/6 mice. Furthermore, maVie16 induces a rapid type I IFN response, which correlated with a marked expansion of pDCs.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Mouse COVID-19 (mCOVID-19) is associated with transient pneumonia and antigen-specific adaptive immunity.</title><p>C57BL/6 mice were intranasally infected with PBS ( = group 0 or PBS) or 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and sacrificed after 2, 5, 7, or 14 days for subsequent analysis. (<bold>A</bold>) Lung tissue virus genome copy numbers (determined by real-time PCR). (<bold>B</bold>) Lung tissue weight. (<bold>C</bold>) Representative lung immunohistochemistry (anti-SARS-CoV-2 nucleocapsid stain, counterstained with hematoxylin) pictures; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 µm. (<bold>D</bold>) Lung pathology score based on histological analysis of lung tissue sections. (<bold>E</bold>) Analysis (by ELISA) of SARS-CoV-2 Spike-specific IgG1, IgG2b, and IgA plasma antibody titers 14 days after infection. (<bold>A, B, D, E</bold>) Mean + SD; symbols represent individual mice; (<bold>A, B, D</bold>): Kruskal–Wallis test (vs. <bold>[A</bold>] day 2 or <bold>[B, D]</bold> group 0) with Dunn’s multiple comparisons test; (<bold>E</bold>) Mann–Whitney test; *p≤0.05; **p≤0.01; ***p≤0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig5-v2.tif"/></fig></sec><sec id="s2-5"><title>Distinct differences in antiviral immunity of BALB/c vs. C57BL/6 mice</title><p>In an attempt to elucidate underlying mechanisms for the different susceptibility of BALB/c and C57BL/6 mice, we infected both mouse strains side by side with 1 × 10<sup>5</sup> TCID<sub>50</sub> of maVie16 and monitored their respective immune responses 3 days later (as BALB/c and C57BL/6 mice showed comparable weight loss and no mortality at this dose and time point; <xref ref-type="fig" rid="fig3">Figure 3</xref>). Both mouse strains exhibited a decline in blood leukocytes, including lymphocytes and NK cells, upon infections with maVie16 (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Also, pulmonary immune cell dynamics did not differ between the strains, except for an expansion of NK cells in BALB/c mice, and elevated pDC numbers in C57BL/6 animals (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Higher NK cell abundance correlated with increased pulmonary IFNγ levels in BALB/c mice, whereas <italic>Il1b</italic> was slightly higher in C57BL/6 animals 3 days after infection (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Plasma cytokine levels (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>), viral loads (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>), as well as spleen and lung weight (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>) were comparable between the two mouse strains. These data identify differences in the early local inflammatory response between maVie16-infected BALB/c as compared to C57BL/6 animals.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>BALB/c mouse COVID-19 (mCOVID-19) is associated with an increased NK cell and interferon response and is ameliorated by IFNγ and TNF blockade.</title><p>BALB/c (B/c) and C57BL/6 (B/6) mice were intranasally inoculated with 10<sup>5</sup> TCID<sub>50</sub> maVie16 (+) or PBS (-). Samples for analyses were collected 3 days after infection. (<bold>A</bold>) Flow cytometry analysis of blood cell populations. (<bold>B</bold>) Flow cytometry analysis of whole lung NK cells and plasmacytoid dendritic cells (pDCs). Density plots represent examples of respective cell populations (NK cells pre-gated from live/CD45<sup>+</sup>/Ly6G<sup>-</sup>/CD3<sup>-</sup>; pDCs pre-gated from live/CD45<sup>+</sup>) (<bold>C</bold>) Lung tissue expression fold change (compared to the respective mean of uninfected samples; analyzed by real-time PCR) of indicated genes. (<bold>D</bold>) Experimental scheme for (<bold>E–G</bold>). BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated intraperitoneally on days 1 and 3 post infection (p.i.) with a mix of 500 µg anti-IFNγ and anti-TNF or with isotype control antibody. (<bold>E</bold>) Body weight and (<bold>F</bold>) temperature kinetics over 5 days after infection. (<bold>G</bold>) Lung weight on day 5 after infection. (<bold>A–C</bold>, <bold>G</bold>) Mean + SD; symbols represent individual mice; differences between infected groups were assessed using the Mann–Whitney test; (<bold>E, F</bold>) mean ± SD; two-way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial body weight or temperature); in panels without respective labels, the groups were not significantly different (p&lt;0.05); *p≤0.05; **p≤0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Comparison of cellular, transcriptional, and organ weight of maVie16-infected BALB/c versus C57BL/6 mice.</title><p>BALB/c (B/c) and C57BL/6 (B/6) mice were intranasally inoculated with 10<sup>5</sup> TCID<sub>50</sub> maVie16 (+) or PBS (-). Samples for analyses were collected 3 days after infection. (<bold>A</bold>) Flow cytometry analysis of blood cell populations. (<bold>B</bold>) Flow cytometry analysis of indicated lung cell populations in whole tissue. (<bold>C</bold>) Lung tissue expression fold change (compared to the respective mean of uninfected samples; analyzed by real-time PCR) of indicated genes. (<bold>D</bold>) Plasma levels of indicated cytokines (assessed by multiplex cytokine analysis). (<bold>E</bold>) Lung tissue virus genome copy numbers (determined by real-time PCR). (<bold>F</bold>) Weight of spleen and lung. (<bold>A–F</bold>) Mean + SD; symbols represent individual mice; differences between infected groups were assessed using the Mann–Whitney test; in panels without respective labels, the groups were not significantly different (p&lt;0.05); *p≤0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Disease parameters of maVie16-infected Ace2-deficient mice, and of infected BALB/c and C57BL/6 mice treated with anti-IFNγ and -TNF blocking antibodies.</title><p>(<bold>A</bold>) Experimental scheme for (B) and (C). BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated intraperitoneally on days 1 and 3 post infection (p.i.) with a mix of 500 µg anti-IFNγ and anti-TNF or with isotype control antibody. (<bold>B</bold>) Lung viral load and (<bold>C</bold>) blood cell numbers 5 days p.i.; (<bold>D</bold>) experimental scheme for (<bold>E</bold>–<bold>I</bold>). C57BL/6 mice were infected with 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated intraperitoneally on days 1 and 3 p.i. with a mix of 500 µg anti-IFNγ and anti-TNF or with isotype control antibody. (<bold>E</bold>) Body weight and (<bold>F</bold>) temperature kinetics over 5 days after infection. (<bold>G</bold>) Lung weight, (<bold>H</bold>) lung viral load, and (<bold>I</bold>) blood cell numbers 5 days p.i.; (<bold>B, C, G–I</bold>) mean + SD; Mann–Whitney test; (<bold>E, F</bold>) mean ± SD; two-way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial body weight or temperature); *p≤0.05; ns, not significant (p&gt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig6-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>A pathogenic role of IFNγ and TNF in disease severity</title><p>Several reports illustrated a correlation between systemic cytokine responses, lung injury, and prognosis in humans suffering from severe COVID-19. A particularly detrimental role was attributed to excessive IFNγ levels (<xref ref-type="bibr" rid="bib17">Grant et al., 2021</xref>). Moreover, an earlier study showed that the combined activity of IFNγ and TNF caused inflammatory types of cell death, which was named PANoptosis, that is, pyroptosis, apoptosis, and necroptosis, and that blocking these cytokines improved disease outcomes in KRT18-hACE2 mice infected with human SARS-CoV-2 (<xref ref-type="bibr" rid="bib28">Karki et al., 2021</xref>). In accordance with these reports and our finding of higher IFNγ levels in highly susceptible BALB/c mice, we tested if blocking IFNγ and TNF might reduce disease severity after maVie16 infection. maVie16-infected (1 × 10<sup>5</sup> TCID<sub>50</sub>) BALB/c mice treated intraperitoneally with a mixture of anti-IFNγ and anti-TNF antibodies (on days 1 and 3 p.i.; <xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>) significantly improved weight loss (<xref ref-type="fig" rid="fig6">Figure 6E</xref>) and decreased lung weights (<xref ref-type="fig" rid="fig6">Figure 6G</xref>), the viral load (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>), as well as circulating monocyte levels (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C</xref>) while it had only minor effects on body temperature (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). In C57BL/6 mice, the same treatment had no effects on body or lung weights, or viral load (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2D, E, G and H</xref>), but significantly improved the altered body temperature and circulating leukocyte numbers (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2F and I</xref>). Though other cytokines and chemokines must be involved, these results underline the therapeutic potential of IFNγ and TNF blockade as COVID-19 treatment.</p></sec><sec id="s2-7"><title>ACE2 expression is essential for <italic>maVie16</italic> infections</title><p>We have previously shown (using <italic>Ace2</italic> mutant mice) that ACE2 is essential for in vivo SARS-CoV infections (<xref ref-type="bibr" rid="bib30">Kuba et al., 2005</xref>). ACE2 is also an important receptor for SARS-CoV-2; however, other receptors have been critically proposed to mediate infections such as neuropilin-1 (<xref ref-type="bibr" rid="bib6">Cantuti-Castelvetri et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Daly et al., 2020</xref>) or CD147 (<xref ref-type="bibr" rid="bib69">Wang et al., 2020a</xref>, <xref ref-type="bibr" rid="bib70">Wang et al., 2020b</xref>). Having developed the maVie16 infection system, we could therefore ask one of the key questions to understand COVID-19: is ACE2 also the essential entry receptor for SARS-CoV-2 infections in a true in vivo infection model? To answer this question, we infected ACE2-deficient male <italic>Ace2<sup>-/y</sup></italic> mice (<xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). In contrast to infected littermate control animals, <italic>Ace2<sup>-/y</sup></italic> mice were fully protected against infection with 5 × 10<sup>5</sup> TCID50 maVie16, maintained stable body weight (<xref ref-type="fig" rid="fig7">Figure 7B</xref>) and temperature (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), and were protected from pneumonia development as indicated by lower lung weight (<xref ref-type="fig" rid="fig7">Figure 7D</xref>) and the absence of any lung pathology (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Resistance to infection was further indicated by the complete absence of nucleocapsid-positive cells in lungs of <italic>Ace2<sup>-/y</sup></italic> animals (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). In conflict with this observation, we still detected similar viral genome copy numbers in both groups (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>), suggesting that this was reflective of initial maVie16 input rather than productive infection. Thus, genetic inactivation of ACE2 protects mice from productive SARS-CoV-2 infections and lung pathologies.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mouse COVID-19 (mCOVID-19) pathology depends on <italic>Ace2</italic> and is improved by recombinant angiotensin-converting enzyme-2 (ACE2) administration.</title><p>(<bold>A</bold>) Experimental scheme for (<bold>B–E</bold>): male <italic>Ace2</italic>-deficient (<italic>Ace2<sup>-/y</sup></italic>) or control (<italic>Ace2<sup>+/y</sup></italic>) mice were infected with 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16. (<bold>B</bold>) Body weight and (<bold>C</bold>) temperature kinetics over 3 days after infection. (<bold>D</bold>) Lung tissue weight 3 days post infection (p.i.). (<bold>E</bold>) Lung histology 3 days after infection (left panels: hematoxylin and eosin stain; right panels: anti-SARS-CoV-2 nucleocapsid immune-stain); black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 µm. (<bold>F</bold>) Experimental scheme for (<bold>G</bold>–<bold>L</bold>). BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (<bold>G</bold>) Body weight and (<bold>H</bold>) temperature kinetics over 5 days after infection. (<bold>I</bold>) Lung weight, (<bold>J</bold>) lung histology (hematoxylin and eosin stain), (<bold>K</bold>) lung viral load, and (<bold>L</bold>) blood cells on day 5 after infection. (<bold>M</bold>) Experimental scheme for (<bold>N</bold>) and (<bold>O</bold>). BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily, intranasally up to day 5 p.i. with 100 µg rms ACE2 or vehicle. The first treatment was administered either 12 hr, 24 hr, or 48 hr p.i. (<bold>N</bold>) Body weight and (<bold>O</bold>) survival over 7 days of infection. (<bold>B, C, G, H, N, O</bold>) mean ± SD; two-way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial body weight or temperature); (<bold>D, I, K, L</bold>) Mann–Whitney test; * p≤0.05; **p≤0.01; ***p≤0.001; ns, not significant (p&gt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Disease parameters of maVie16-infected Ace2-deficient mice, and of infected BALB/c and C57BL/6 mice treated with recombinant mouse angiotensin-converting enzyme-2 (ACE2).</title><p>(<bold>A</bold>) Experimental scheme for (<bold>B</bold>): male <italic>Ace2</italic>-deficient (<italic>Ace2<sup>-/y</sup></italic>) or control (<italic>Ace2<sup>+/y</sup></italic>) mice were infected with 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16. (<bold>B</bold>) Lung viral load 3 days post infection (p.i.). (<bold>C</bold>) Experimental scheme for (<bold>D</bold>). BALB/c mice were infected with 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (<bold>D</bold>) Lung histology (anti-SARS-CoV-2 nucleocapsid immune stain) on day 5 after infection; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; arrowheads indicate infected (nucleocapsid-positive) cells; scale bars represent 100 µm. (<bold>E</bold>) Experimental scheme for (<bold>F–J</bold>). C57BL/6 mice were infected with 5 × 10<sup>5</sup> TCID<sub>50</sub> maVie16 and treated daily intranasally up to day 4 p.i. with 100 µg rms ACE2 or vehicle (the first treatment was administered together with virus). (<bold>F</bold>) Body weight and (<bold>G</bold>) temperature kinetics over 5 days after infection. (<bold>H</bold>) Lung weight, (<bold>I</bold>) lung viral load, and (<bold>J</bold>) blood cells on day 5 after infection; (<bold>K</bold>) Experimental scheme for LBALB/c mice were infected with 105 TCID50 maVie16 and treated daily, intranasally up to day 5 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle. The first treatment was administered either 12h, 24h or 48h p.i. (<bold>L</bold>) Body temperature over 7 days of infection. (<bold>B, H–J</bold>) mean + SD; Mann–Whitney test; (<bold>F, G, L</bold>) mean ± SD; two-way ANOVA with Dunnett’s multiple comparisons test (vs. the respective initial body weight or temperature); **p≤0.01; ***p≤0.001; ns, not significant (p&gt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74623-fig7-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Inhalation of ACE2 can protect from <italic>maVie16</italic> infections</title><p>To test whether ACE2 could also be used therapeutically to protect from maVie16-induced lung pathologies in BALB/c and C57BL/6 mice, we performed prophylactic inhalation treatments with recombinant murine soluble (rms) ACE2. maVie16-infected (1 × 10<sup>5</sup> TCID<sub>50</sub>) BALB/c mice that were treated with rmsACE2 (<xref ref-type="fig" rid="fig7">Figure 7F</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>) did not lose body weight (<xref ref-type="fig" rid="fig7">Figure 7G</xref>), developed less hypothermia (<xref ref-type="fig" rid="fig7">Figure 7H</xref>), exhibited lower lung weights (<xref ref-type="fig" rid="fig7">Figure 7I</xref>), and were largely protected from pneumonia (day 5 p.i.; <xref ref-type="fig" rid="fig7">Figure 7J</xref>), had lower lung viral loads (<xref ref-type="fig" rid="fig7">Figure 7K</xref>), and fewer blood neutrophils (<xref ref-type="fig" rid="fig7">Figure 7L</xref>) than vehicle-treated animals, indicating marked prevention of mCOVID-19 development. Further, we found fewer SARS-CoV-2 nucleocapsid-positive cells in lungs of BALB/c animals treated with rmsACE2 5 days after infection with maVie16 as compared to controls (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Similarly, rmsACE2 treatment of maVie16-infected (5 × 10<sup>5</sup> TCID<sub>50</sub>) C57BL/6 mice (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>) prevented weight loss and reduced the viral load (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F and G</xref>, respectively) while it did not affect temperature, lung weight, and blood leukocyte numbers (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1G, H and J</xref>, respectively). Strikingly, inhalative ACE2 therapy was still fully protective when applied 12 hr post infection (<xref ref-type="fig" rid="fig7">Figure 7M–O</xref>). While mice that received inhalation therapy at later time points post infection still developed disease (<xref ref-type="fig" rid="fig7">Figure 7N</xref>), mortality was completely prevented or reduced when inhalative treatment was applied 24 hr or 48 hr post infection, respectively (<xref ref-type="fig" rid="fig7">Figure 7O</xref>). These data show that inhalation of rmsACE2 can markedly prevent maVie16-induced (m)COVID-19.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>With maVie16, we here generated a novel tool to study and experimentally dissect COVID-19 in vivo. Our passaging protocol led to an initial fast adaptation of the BavPat1 to the new host, indicated by a rapid increase in virus genome copy number found in the lung. This increased mouse infectivity coincided with the appearance of a Spike protein mutation at position 498, which was intentionally introduced using an engineering approach by the Baric group in an earlier attempt to increase mouse specificity of SARS-CoV-2 (<xref ref-type="bibr" rid="bib15">Dinnon et al., 2020</xref>). Interestingly, another maVie16 Spike protein mutation (at position 493) was also found in the mouse-adapted variant of the engineered virus after 10 passages through BALB/c mice (<xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Leist et al., 2020</xref>) and reported to improve Spike-mAce2 interaction (<xref ref-type="bibr" rid="bib1">Adams et al., 2021</xref>). In support of their apparent mouse specificity, Q498H or Q493R mutations had been only sporadically observed in a few patient samples (16 and 196, respectively, according to the GISAID database; <xref ref-type="bibr" rid="bib59">Shu and McCauley, 2017</xref>) until recently. However, the most recent VOC Omicron/B.1.1.529 harbors the same Q493R mutation and in addition contains Q498R, which leads to the introduction of a basic amino acid (arginine), similar to maVie16’s Q498H mutation. The K417T Spike protein mutation was also found in the Gamma/P1 SARS-CoV-2 VOC (<xref ref-type="bibr" rid="bib68">Voloch, 2020</xref>), and the same lysine was changed to an asparagine in the Omicron/B1.1.529 and the Beta/B.1.351 VOC (<xref ref-type="bibr" rid="bib64">Tegally et al., 2020</xref>). Importantly, Beta/B.1.351 and Gamma/P1 SARS-CoV-2 have been shown to replicate in laboratory mice (<xref ref-type="bibr" rid="bib46">Montagutelli et al., 2021</xref>) and in both K417T/N was exclusively observed in conjunction with the mutations N501Y and E484K. While N501Y is suspected to boost infectivity, E484K might contribute to antibody escape and immune evasion. In its interaction with hACE2, E484 is postulated to form a salt bridge with K31 in hACE2, while the neighboring D30 interacts with K417. Mutating K417 and E484 leads to an intramolecular salt bridge between D30 and K31 in hACE2, having only minor effects on receptor interaction (<xref ref-type="bibr" rid="bib9">Cheng et al., 2021</xref>). As outlined above, with aspartic acid replaced by asparagine at position 30 in mACE2, Spike protein amino acid K417 no longer has a strong interaction partner and mutation to T417 in maVie16 is favorable. These data indicate that K417T per se might not itself be involved in immune escape mechanisms, but rather emerged to stabilize the interaction with mACE2.</p><p>Our in silico modeling provides strong evidence that these Spike protein mutations in maVie16 support the molecular interaction with mACE2, thereby facilitating infections and the development of severe COVID-19 in mice. At the same time, the multibasic S1/S2 furin cleavage site (681-PRRAR) as well as the S2′ cleavage site (at 815R) were maintained, rendering maVie16 Spike accessible for proteolytic processing by endogenous proteases such as TMPRSS2 or furin, which are essential for productive infection (<xref ref-type="bibr" rid="bib63">Takeda, 2022</xref>) and highly conserved between mice and men (<xref ref-type="bibr" rid="bib67">Vaarala et al., 2001</xref>). Structural analysis did not support an altered binding of maVie16 Spike to hACE2, which was confirmed by propagation experiments with BavPat1 and maVie16 in human Caco-2 cells. In light of the debate about the origin of Omicron/B.1.1.529, we believe that our data, in particular the co-appearance of Q493 and Q498 mutations in the Omicron/B.1.1.529 variant and maVie16, support the idea of Omicron being the result of reverse zoonosis and viral evolution in an animal reservoir (<xref ref-type="bibr" rid="bib32">Kupferschmidt, 2021</xref>).</p><p>While inducing profound disease and mortality in BALB/c mice, maVie16 also induced substantial body weight loss and pneumonia in adult C57BL/6 mice. In addition, C57BL/6 mCOVID-19 recapitulated critical immunological aspects observed in human COVID-19, including peripheral leuko- and lymphopenia, pneumonia, and antigen-specific adaptive immunity. The time to symptom onset was approximately 2–3 days, which is faster than reported in humans (around 5 days) (<xref ref-type="bibr" rid="bib37">Li et al., 2020</xref>) and might be explained by the route of infection and subsequent high viral dose in the lower airways, as opposed to droplet infection of the upper respiratory tract in humans. In addition, mCOVID-19 is characterized by an early pDC mobilization in blood and lung, associated with a fast pulmonary type I IFN response. This correlates with the peak of viral burden, which subsequently declines. However, as others have shown that IFNs play an ambiguous role during COVID-19 (<xref ref-type="bibr" rid="bib26">Israelow et al., 2020</xref>), further experiments (e.g., using IFNAR1-deficient animals or type I IFN blocking antibodies) will be required to address the direct impact of type I IFNs on <italic>maVie16</italic> clearance in vivo. The susceptibility of C57BL/6 animals proves particularly valuable since a large number of genetically modified mice is available on this background. A side-by-side comparison of BALB/c versus C57BL/6 mice revealed increased lung expression of type II IFN and IFN-driven genes in the BALB/c background, supporting the notion that pronounced inflammation is linked to more severe pathology. A detrimental role for cytokines, specifically IFNγ and TNF, had been previously associated with severe COVID-19 and experimentally identified as a risk factor for severe disease in SARS-CoV-2-infected KRT18-hACE2 mice by causing a form of inflammatory cell death termed <italic>PANoptosis</italic> (<xref ref-type="bibr" rid="bib28">Karki et al., 2021</xref>). We also tested this hypothesis and found that administration of IFNγ- and TNF-blocking antibodies significantly reduced disease burden and inflammation in maVie16-infected BALB/c mice. The role of other cytokines and chemokines as well as innate antiviral immunity or defined cell populations can now be genetically and experimentally dissected using our maVie16 infection model.</p><p>Several studies based on crystallography (<xref ref-type="bibr" rid="bib76">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Yan et al., 2020</xref>), modeling (<xref ref-type="bibr" rid="bib56">Rodrigues et al., 2020</xref>), or in vitro experiments (<xref ref-type="bibr" rid="bib5">Cai et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Monteil et al., 2020</xref>) propose ACE2 as the main entry receptor for SARS-CoV-2. The relevance of ACE2 is further supported by in vivo experiments using KRT18-hACE2 mice (<xref ref-type="bibr" rid="bib49">Oladunni et al., 2020</xref>) or viral vector-mediated hACE2 delivery systems (<xref ref-type="bibr" rid="bib53">Rathnasinghe et al., 2020</xref>). Although these experiments have shown that ACE2 expression is sufficient for infection, definitive proof of an essential in vivo role of ACE2 in COVID-19 has not been provided so far. This is of particular importance because additional receptors have been proposed that could also permit SARS-CoV2 infections (<xref ref-type="bibr" rid="bib6">Cantuti-Castelvetri et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Daly et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2020b</xref>). Using <italic>Ace2</italic>-deficient mice, we here demonstrate the strict dependence of maVie16 infectivity and pathogenicity on ACE2 expression in vivo. Furthermore, we exploited this mechanistic insight and treated animals with rmsACE2 inhalation and observed a substantial protection of BALB/c and C57BL/6 mice from developing mCOVID-19. A recently published genome-wide association study across more than 50,000 COVID-19 patients and more than 700,000 noninfected individuals revealed a rare variant that was associated with downregulated <italic>ACE2</italic> expression and reduced risk of COVID-19 (<xref ref-type="bibr" rid="bib24">Horowitz et al., 2021</xref>), providing additional evidence for the importance of ACE2 for SARS-CoV-2 infection in humans. The principal effectiveness of recombinant human soluble (rhs) ACE2 towards SARS-CoV-2 was demonstrated earlier in organoids as it slowed viral replication in this setting (<xref ref-type="bibr" rid="bib47">Monteil et al., 2020</xref>). It has been recently proposed that soluble ACE2 might enhance SARS-CoV-2 infections (<xref ref-type="bibr" rid="bib78">Yeung et al., 2021</xref>), however, our data do not support this. Moreover, using hamsters (<xref ref-type="bibr" rid="bib21">Higuchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Linsky et al., 2020</xref>) and the KRT18-hACE2 mouse model (<xref ref-type="bibr" rid="bib20">Hassler et al., 2021</xref>), it has also been shown that different forms of ACE2 can protect from disease, providing – together with our novel murine COVID-19 model – preclinical proof of concept that ACE2 can be used as a therapy. RhsACE2, prepared in the same way as rmsACE2 we used for our inhalation experiments (<xref ref-type="bibr" rid="bib47">Monteil et al., 2020</xref>), is now being tested in clinical trials in COVID-19 patients with first promising results (<xref ref-type="bibr" rid="bib83">Zoufaly et al., 2020</xref>). Considering the emergence of variants that can escape in part vaccine efficacy and approved antibody therapies (<xref ref-type="bibr" rid="bib79">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Zhou et al., 2021</xref>) and the fact that these variants have been apparently selected for better ACE2 binding (<xref ref-type="bibr" rid="bib65">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Yuan et al., 2021</xref>), ACE2 inhalation has the potential to prevent or treat early stages of SARS-CoV-2 infections irrespective of the virus variant. However, whether inhalable ACE2 indeed constitutes a universal strategy against current and future SARS-CoV-2 variants needs careful testing in clinical trials.</p><p>Overall, we here report the development of a novel mouse-adapted SARS-CoV-2, which induces mCOVID-19 in both BALB/c and C57BL/6 backgrounds. Our findings on the essential role of ACE2 in in vivo infections and of recombinant mACE2 administration and IFNγ/TNF blocking as therapeutic options provide a first glimpse of the potential of this new tool to increase our understanding of COVID-19 in vivo to foster the discovery of novel therapeutic options.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Reagents and resources</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, male)</td><td align="left" valign="bottom">BALB/cJ</td><td align="left" valign="bottom">Own colony, Jackson Labs</td><td align="left" valign="bottom">JAX #000651</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, male)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">Own colony, Jackson Labs</td><td align="left" valign="bottom">JAX #000664</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, male)</td><td align="left" valign="bottom">KRT18-hACE2</td><td align="left" valign="bottom">Own colony, Jackson Labs</td><td align="left" valign="bottom">JAX #034860</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, male)</td><td align="left" valign="bottom">Ace2-/y</td><td align="left" valign="bottom">Own colony, Jackson Labs <break/><xref ref-type="bibr" rid="bib12">Crackower et al., 2002</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (SARS-CoV-2)</td><td align="left" valign="bottom">BavPat1/2020</td><td align="left" valign="bottom">Charité, Berlin, Germany</td><td align="left" valign="bottom">European Virology Archive# 026V-03883</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Strain, strain background (SARS-CoV-2)</td><td align="left" valign="bottom">maVie16</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Chlorocebus</italic>)</td><td align="left" valign="bottom">Vero</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-81</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Chlorocebus</italic>)</td><td align="left" valign="bottom">Vero TMPRSS2 (OE)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">Caco-2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB37</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Fixable Viability Dye eFluor 780</td><td align="left" valign="bottom">Thermo Fisher, eBioscience</td><td align="left" valign="bottom">Cat# 65-0865-14</td><td align="left" valign="bottom">FC (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-mouse CD16/32 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101320; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1574975">AB_1574975</ext-link></td><td align="left" valign="bottom">FC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV510 anti-mouse CD45 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103138; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563061">AB_2563061</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD45 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103106; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312971">AB_312971</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/dazzle 594 anti-mouse CD45.2 (monoclonal mouse)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 109845; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2564176">AB_2564176</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD45R (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103208; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312993">AB_312993</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse F4/80 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 123110; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893486">AB_893486</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 700 anti-mouse CD11b (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101222; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493705">AB_493705</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine7 anti-mouse CD11b (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101215; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312798">AB_312798</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 605 anti-mouse CD11b (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101237; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11126744">AB_11126744</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD11b (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101208; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312791">AB_312791</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD11c (monoclonal Armenian hamster)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 117310; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313779">AB_313779</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-Texas Red anti-mouse CD11c (monoclonal Armenian hamster)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# MCD11C17;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10373971">AB_10373971</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD11c (monoclonal Armenian hamster)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 557401; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396684">AB_396684</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 510 anti-mouse Ly-6C (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128033; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562351">AB_2562351</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cy7 anti-mouse Ly-6G (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127617; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1877262">AB_1877262</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse Ly-6G (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127605; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1236488">AB_1236488</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV510 anti-mouse Ly-6G (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127633; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562937">AB_2562937</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse Ly6G (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127608; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186099">AB_1186099</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP-Cy5.5 Siglec-F (monoclonal rat)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 565526; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2739281">AB_2739281</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">eFluor 450 anti-mouse MHC Class II (I-A/I-E) (monoclonal rat)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 48-5321-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1272204">AB_1272204</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV605 anti-mouse CD115 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135517; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562760">AB_2562760</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse CD19 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115506; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313641">AB_313641</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV605 anti-mouse CD19 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115540; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563067">AB_2563067</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD19 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115507; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313642">AB_313642</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse CD3 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100204; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312661">AB_312661</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Dazzle 594 anti-mouse CD3 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100245; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2565882">AB_2565882</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cy5.5 anti-mouse CD3 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100217; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1595597">AB_1595597</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">eFluor450 anti-mouse CD3 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100213; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493644">AB_493644</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD3 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100205; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312662">AB_312662</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse CD4 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100406; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312691">AB_312691</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AF700 anti-mouse CD4 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100429; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493698">AB_493698</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cy5.5 anti-mouse CD4 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100433; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893330">AB_893330</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD4 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100407; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312692">AB_312692</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AF700 anti-mouse CD8a (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100729; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493702">AB_493702</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Pacific Blue anti-mouse CD8a (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100728; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493426">AB_493426</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD8a (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100707; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312746">AB_312746</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse TCRβ chain (monoclonal Armenian hamster)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 109207; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313430">AB_313430</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse TCRγδ (monoclonal Armenian hamster)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 118107; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313831">AB_313831</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cy5.5 anti-mouse NK-1.1 (monoclonal mouse)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108727; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2132706">AB_2132706</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse NK-1.1 (monoclonal mouse)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108709; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313396">AB_313396</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse FcεRIα (monoclonal Armenian hamster)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 134307; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1626104">AB_1626104</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cy7 anti-mouse CD117 (c-kit) (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 105813; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313222">AB_313222</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV421 anti-mouse CD193 (CCR3) (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 144517; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2565743">AB_2565743</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 anti-mouse CD49b (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108912; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_492880">AB_492880</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AF700 anti-mouse CD49b (monoclonal rat)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 56-5971-80; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2574506">AB_2574506</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Dazzle 594 anti-mouse CD64 (FCγRI) (monoclonal mouse)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 139319; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2566558">AB_2566558</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AF700 anti-mouse CD43 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 143213; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2800660">AB_2800660</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD44 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103012; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312963">AB_312963</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV510 anti-mouse CD138 (monoclonal rat)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 563192; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2738059">AB_2738059</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cy5.5 anti-mouse CD21/CD35 (CR2/CR1) (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 123416; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1595490">AB_1595490</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AF647 anti-mouse CD23 (monoclonal rat)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 562826; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2737821">AB_2737821</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-Cy7anti-mouse CD93 (AA4.1) (monoclonal rat)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 25-5892-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469659">AB_469659</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">eFluor450 anti-mouse CD90.2 (Thy1.2) (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 140305; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10645335">AB_10645335</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse MERTK (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 151504; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617035">AB_2617035</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse MERTK (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 151505; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617036">AB_2617036</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV605 anti-mouse CD127 (IL-7α) (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135025; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562114">AB_2562114</ext-link></td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">eFluor450 anti-mouse IgM (monoclonal rat)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 48-5890-82;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10671539">AB_10671539</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse IgD (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 405704; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315026">AB_315026</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse IgA (monoclonal rat)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 12-4204-83; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_465918">AB_465918</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV605 anti-mouse CD62L (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 104438; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563058">AB_2563058</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cy7 anti-mouse TER-119 (monoclonal rat)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 116223; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2137788">AB_2137788</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse IgG1 (monoclonal rat)</td><td align="left" valign="bottom">BD Pharmingen</td><td align="left" valign="bottom">Cat# 553441</td><td align="left" valign="bottom">ELISA (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse IgG2b (monoclonal rat)</td><td align="left" valign="bottom">BD Pharmingen</td><td align="left" valign="bottom">Cat# 553393</td><td align="left" valign="bottom">ELISA (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse IgA (polyclonal goat)</td><td align="left" valign="bottom">Southern Biotech</td><td align="left" valign="bottom">Cat# 1040-08</td><td align="left" valign="bottom">ELISA (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SARS nucleocapsid (polyclonal rabbit)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NB100-56576</td><td align="left" valign="bottom">IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-rabbit IgG (polyclonal goat)</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">Cat# BA-1000</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse TNF (neutralizing) (monoclonal rat)</td><td align="left" valign="bottom">In house</td><td align="left" valign="bottom">Clone XT22</td><td align="left" valign="bottom">2 × 500 µg/200 µl/mouse i.p.</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IFNg (neutralizing) (monoclonal rat)</td><td align="left" valign="bottom">In house</td><td align="left" valign="bottom">Clone XMG 1.2</td><td align="left" valign="bottom">2 × 500 µg/200 µl/mouse i.p.</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ß-galactosidase (IgG1 isotype control) (monoclonal rat)</td><td align="left" valign="bottom">In house</td><td align="left" valign="bottom">Clone GL113</td><td align="left" valign="bottom">2 × 500 µg/200 µl/mouse i.p.</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pIRES2-AcGFP1 (Plasmid)</td><td align="left" valign="bottom">Clontech</td><td align="left" valign="bottom">Cat# 632435</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pIRES2-SC2quant</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"> Plasmid containing a PCR-amplified sequence of BavPat1; used as standard for quantification of virus genome copy numbers</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pBluescript KS(-)</td><td align="left" valign="bottom">Stratagene</td><td align="left" valign="bottom">Cat# 212208</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pBMN-I-GFP</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Plasmid 1736</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pBMN-TMPRSS2-I-GFP</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Plasmid containing the PCR-amplified coding sequence of human TMPRSS2; used to transfect Vero cells to enhance in vitro virus propagation</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"> CoV-F3_XhoI</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CTCGAGTTTCCTGGTGATTCTTCTTCAGGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"> CoV-R3_BamHI</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CCTAGGTCTGAGAGAGGGTCAAGTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CoV-F3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref></td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TCCTGGTGATTCTTCTTCAGGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CoV-R3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref></td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TCTGAGAGAGGGTCAAGTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"> CoV-P3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref></td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">AGCTGCAGCACCAGCTGTCCA (FAM/TAMRA-labeled)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Adar1</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GATGACCAGTCTGGAGGTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Adar1</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GCAGCAAAGCCATGAGATCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Eif2ak2</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">AAGTACAAGCGCTGGCAGAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Eif2ak2</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GCACCGGGTTTTGTATCGAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ifng</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">ACTGGCAAAAGGATGGTGACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ifng</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TGGACCTGTGGGTTGTTGAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ifit1</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CAGCAACCATGGGAGAGAATGCTGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Ifit1</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GGCACAGTTGCCCCAGGTCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il1b</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CAAAATACCTGTGGCCTTGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il1b</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TACCAGTTGGGGAACTCTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il6</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CCACGGCCTTCCCTACTTCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il6</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TGCAAGTGCATCGTTGTTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il10</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TGAGGCGCTGTCATCGATTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Il10</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">CATGGCCTTGTAGACACCTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Tgfb</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">AGCCCGAAGCGGACTAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Tgfb</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">TCCACATGTTGCTCCACACT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Tnf</italic>_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GCGTGGAGCTGAGAGATAACC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Tnf</italic>_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers, Microsynth</td><td align="left" valign="bottom">GATCCCAAAGTAGACCTGCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human TMPRSS2_fwd</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AACCTGGGCGCCTGGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human TMPRSS2_rev</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACGTCAAGGACGAAGACCATGTG</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Collagenase I</td><td align="left" valign="bottom">Gibco/Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">17018029</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">DNAse I</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">DN25</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant SARS-CoV-2 Spike protein ectodomain</td><td align="left" valign="bottom">Reingard Grabherr, BOKU Vienna <break/><xref ref-type="bibr" rid="bib29">Klausberger et al., 2021</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">mrsACE2</td><td align="left" valign="bottom">In house (APEIRON Biologics) <break/><xref ref-type="bibr" rid="bib47">Monteil et al., 2020</xref><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ROTI Prep RNA Mini</td><td align="left" valign="bottom">Carl Roth</td><td align="left" valign="bottom">Cat# 8485.1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAamp Viral RNA Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 52904</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">E.Z.N.A Viral RNA kit</td><td align="left" valign="bottom">Omega Bio-tek</td><td align="left" valign="bottom">Cat# R6874</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">qScript cDNA Synthesis Kit</td><td align="left" valign="bottom">Quantabio</td><td align="left" valign="bottom">Cat# 95047-500</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PerfeCTa SYBR Green SuperMix</td><td align="left" valign="bottom">Quantabio</td><td align="left" valign="bottom">Cat# 95055</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">VectastainABC kit</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">Cat# PK-6100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DAB Substrate kit</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">Cat# SK-4100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LEGENDplex Macrophage/Microglia Panel</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 740846</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LEGENDplex MU Th Cytokine Panel V02</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 740741</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium pyruvate (100 mM)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11360070</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin streptomycin (10,000 U/ml)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 15140122</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MEM nonessential amino acids (100×)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11140050</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RLT Plus</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 1053393</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Mercaptoethanol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# M3148</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Antigen Unmasking Solution</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">Cat# H3300-250</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hematoxylin solution (Mayer’s)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# MHS16</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 9.1</td><td align="left" valign="bottom">GraphPad Software, Inc.</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">Becton, Dickinson and Company</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dulbecco’s Modified Eagle’s Medium</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 10564011</td><td align="left" valign="bottom">High glucose, GlutaMAX, HEPES</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Fetal bovine serum</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# F9665</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Goat serum</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NBP2-23475</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Methods</title><sec id="s4-2-1"><title>Animal studies</title><p>For passaging, dose–response and time-course experiments, male 10–12-week-old BALB/cJ and C57BL/6J mice obtained from Janvier or bred and maintained at the animal facility of the Medical University of Vienna were used. Mice expressing human ACE2 under control of the human <italic>KERATIN-18</italic> (KRT18) promoter (Tg[KRT18-Ace2])2<sup>Prlmn</sup> (<xref ref-type="bibr" rid="bib44">McCray et al., 2007</xref>) (herein referred to as KRT18-huACE2 mice) were obtained from Jackson Labs and bred in the local animal facility. Ace-2-deficient (<italic>Ace2<sup>-/-</sup></italic>) mice were generated as described (<xref ref-type="bibr" rid="bib12">Crackower et al., 2002</xref>) and bred at the animal facility of the Institute of Molecular Biotechnology Austria, Vienna. All experiments involving SARS-CoV-2 or its derivatives were performed in Biosafety Level 3 (BSL-3) facilities at the Medical University of Vienna and performed after approval by the institutional review board of the Austrian Ministry of Sciences (BMBWF-2020-0.253.770) and in accordance with the directives of the EU.</p></sec><sec id="s4-2-2"><title>Cell lines</title><p>Simian kidney Vero cells were provided by Christoph Steininger (Medical University of Vienna, ATCC CCL81). To improve in vitro SARS-CoV-2 propagation (<xref ref-type="bibr" rid="bib43">Matsuyama et al., 2020</xref>), Vero cells were transduced as previously described (<xref ref-type="bibr" rid="bib41">Machacek et al., 2016</xref>) with the retroviral expression vector pBMN-I-GFP carrying human TMPRSS2, amplified from the human lung adenocarcinoma cell line Calu-3 (ATCC HTB-55, provided by Walter Berger, Medical University of Vienna) and subcloned via the pBluescript KS(-) plasmid. The transduced cell population was subsequently sorted based on GFP expression to &gt;99% purity, creating Vero<sup>TMPRSS2</sup> cells. Both cell lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Gibco/Thermo Fisher) supplemented with GlutaMAX, 10% fetal calf serum (FCS; Sigma), 1% MEM nonessential amino acids solution (Thermo Fisher), and 1% sodium pyruvate (Thermo Fisher) and grown at 37°C at 5% CO<sub>2</sub>.</p></sec><sec id="s4-2-3"><title>SARS-CoV-2 strains, virus propagation, and growth curves</title><p>The human SARS-CoV-2 isolate BetaCoV/Munich/BavPat1/2020 (referred to as BavPat1) was kindly provided by Christian Drosten, Charité, Berlin (<xref ref-type="bibr" rid="bib57">Rothe et al., 2020</xref>), and distributed by the European Virology Archive (Ref-SKU: 026V-03883). maVie16 was generated in this study as described. To generate high titer viral stocks, TMPRSS2-overexpressing Vero cells (Vero<sup>TMPRSS2</sup>) were grown on 175 cm<sup>2</sup> tissue culture flasks and were infected with BavPat1 or maVie16 at a multiplicity of infection (MOI) of 0.1 in Vero cell culture medium (described above) with reduced (2%) FCS content. The inoculum was calculated based on stock concentrations determined using TCID<sub>50</sub> assays (described below) assuming that 1 * PFU/ml = 0.7 * TCID<sub>50</sub>/ml applying the Poisson distribution for the estimation of PFU. Supernatants from infected cells were collected after 48–72 hr, clarified by centrifugation (3820 × <italic>g</italic>, 15 min), and stored in aliquots at –80°C. To determine stock concentrations, TCID<sub>50</sub> assays were conducted by infecting Vero cells with 150 µl of 10-fold serial dilutions of viral samples (cell supernatant, cell-free lung homogenate), followed by incubation at 37°C. Cytopatic effects were analyzed by microscopy after 72 hr and titers were calculated by the method of <xref ref-type="bibr" rid="bib54">Reed and Muench, 1938</xref>. To compare infectivity and viral replication, Vero cells or Caco-2 cells were infected with BavPat1 or maVie16 at a MOI of 0.05 and incubated at 37°C. After 1 hr, the viral inoculum was removed and replaced with medium. At designated time points, supernatants were removed, cleared by centrifugation (500 × <italic>g</italic>, 5 min), and stored at –80°C until further processing for RNA isolation and quantification of genome copies.</p></sec><sec id="s4-2-4"><title>Generation of a mouse-adapted SARS-CoV-2 virus, maVie16</title><p>Mouse adaptation of SARS-CoV-2 and generation of maVie16 were achieved by serial passaging through lungs of BALB/c mice (16 passages). Briefly, three anesthetized (isoflurane), male 10–12-week-old BALB/c mice were infected intranasally (i.n.) with 2 × 10<sup>6</sup> TCID<sub>50</sub> BavPat1 in 50 µl. After 3 days, the mice were euthanized and their lungs were homogenized using a rotor/stator homogenizer in eightfold volume of DMEM. After removal of aliquots for RNA isolation (see below), the lung homogenates were cleared by centrifugation (3820 × <italic>g</italic>, 6 min), filtered using round-bottom tubes with cell-strainer cap (Falcon), pooled, and administered i.n. to the next group of anesthetized naïve male BALB/c mice. This process of i.n. infection and harvest was repeated 15 times, and weight loss and body temperature (measured with a rectal rodent thermometer; Braintree Scientific) were monitored as readouts of viral pathogenicity. Viral load was quantified by detection of SARS-CoV-2 RNA in the cleared lung homogenate described below. The maVie16 stock (collected from the lungs of mice infected with passage 15) was prepared in Vero cells as described above. maVie16 virus will be shared with research labs fulfilling respective safety requirements upon request and execution of a material transfer agreement.</p></sec><sec id="s4-2-5"><title>Mouse model of COVID-19 (mCOVID-19) and tissue collection</title><p>For dose–response and time-course experiments, male 10–12-week-old BALB/c mice and C57BL/6 mice were infected i.n. with 50 µl DMEM containing indicated doses of maVie16. Clinical signs of disease (loss of body weight and/or temperature) were monitored at indicated time points. Mice were euthanized by cervical dislocation at indicated endpoints for sample collection or whenever they approached 75% of their starting body weight, in accordance with ethical guidelines.</p><p>Blood was collected from euthanized animals from the vena cava and transferred to MiniCollect tubes (Greiner) containing K<sub>3</sub>EDTA. 75 µl of blood per flow cytometry panel were removed, treated for erythrocyte lysis using ACK buffer (150 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM Na<sub>2</sub>EDTA, pH 7.2–7.4), and processed for flow cytometry as described below. The remaining blood was centrifuged 10 min at 1700 × <italic>g</italic>, followed by plasma collection and storage at –80°C.</p><p>Whole lungs were harvested and weights recorded. The left lung was assigned to histology and fixed in 7.5% buffered formaline. At least 50 µg of the right lung were kept for tissue homogenization as described above. For total lung RNA, 80 µl of homogenized tissue was lysed in RLT Buffer (QIAGEN) containing 2-mercaptoethanol (Sigma-Aldrich) and stored at –80°C until further use. The remaining homogenized lung tissue was centrifuged (3820 × <italic>g</italic>, 6 min) and the cleared homogenate was frozen at –80°C for subsequent viral RNA isolation (see below). To reprepare lung single-cell suspensions for flow cytometry, the remaining right lungs were minced in gentleMACS tubes with the gentleMACS dissociator (Miltenyi Biotec; program m_lung_01) and digested in 2.5 ml of digestion medium (RPMI medium [Gibco] containing 5% FCS, 250 U/ml collagenase I [Gibco], and 20 U/ml DNase I [Sigma]) by shaking at 100 rpm for 30 min at 37°C. Digested samples were then homogenized with the gentleMACS dissociator (program m_lung_02) and filtered over a 70 µm cell strainer (BD Biosciences). After centrifugation (500 × <italic>g</italic>, 5 min, 4°C), the cell pellet was treated for 5 min with ACK to lyse erythrocytes. After stopping erythrocyte lysis by addition of PBS 1% bovine serum albumin (BSA; Sigma), cells were passaged over a 40 µm cell strainer (BD Biosciences) and resuspended for subsequent antibody staining (see below).</p></sec><sec id="s4-2-6"><title>RNA isolation and gene expression analysis by real-time PCR</title><p>Total RNA was extracted from mouse lung homogenates, and viral RNA was extracted from cleared mouse lung homogenates and cell culture supernatants using the following commercially available kits according to the manufacturer’s instructions: for viral RNA extraction, QIAamp Viral RNA Mini Kit (QIAGEN) and E.Z.N.A Viral RNA kit (Omega Bio-tek) were used. Quantification of viral RNA was performed by quantitative reverse transcription PCR (RT-qPCR) as described below. For total RNA extraction, the samples were passed through a QIAshredder (QIAGEN) to reduce viscosity and subsequently RNA was isolated using the ROTI Prep RNA Mini kit (Carl Roth). After isolation, RNA concentration was measured using a NanoVue Plus Spectrophotometer (GE Healthcare). For cDNA synthesis, 0.5 µg RNA from each sample was reverse-transcribed using the qScript cDNA Synthesis Kit (Quantabio). For subsequent qPCR reactions, PerfeCTa SYBR Green SuperMix (Quantabio) was used in a total reaction volume of 15 µl. TaqMan primer/probes for mouse inflammatory genes were purchased from Microsynth and are listed below. RT-PCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) with the following conditions: 95°C for 3 min, followed by 45 amplification cycles (15 s at 95°C) and elongation (1 min at 60°C).</p></sec><sec id="s4-2-7"><title>SARS-CoV-2 quantification by real-time PCR</title><p>To generate a standard curve for quantification of virus genome copy numbers, a 144 bp fragment of the SARS-CoV-2 genome was amplified from BavPat1 cDNA (generated using the qScript XLT cDNA supermix [Quanta Bio] with RNA purified with the QIAamp Viral RNA Mini Kit) with simultaneous insertion of XhoI (5′ end) and BamHI (3′ end) restriction site overhangs by PCR (Touchdown from 70°C to 55°C over 35 cycles) using primers CoV-F3_XhoI and CoV-R3_BamHI and Q5 High-Fidelity DNA Polymerase (New England Biolabs). The purified PCR product was then cloned into pIRES2-GFP1 (Clontech) via directional restriction digest and ligation (XhoI and BamHI Fast Digest enzymes from Thermo Fisher; Ligase from New England Biolabs) to generate the plasmid pIRES2-SC2quant. pIRES2-SC2quant was transfected into One Shot TOP10 Chemically Competent <italic>Escherichia coli</italic>, followed by amplification from single-cell colonies, isolation of plasmid DNA (using QIAPrep Mini and Midi Prep Kits [QIAGEN]) and validation of the construct by sequencing (Microsynth). Based on the molecular weight of the pIRES2-SC2quant plasmid (3344181.19 Da), a log<sup>10</sup> dilution series of the plasmid was prepared to contain 0–10<sup>10</sup> plasmid copies. These dilutions were included on each plate for quantification of viral load in tissue samples by qPCR. The qPCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) using primers CoV-F3 and CoV-R3 with (FAM/TAMRA-labeled) probe CoV-P3 (all at 10 µM and all obtained from Microsynth) and the Ultraplex 1-Step ToughMix ROX (Quantabio), with an initial 10 min 50°C incubation for cDNA synthesis, followed by 40 amplification cycles of denaturation (15 s at 95°C) and elongation (1 min at 60°C) (<xref ref-type="bibr" rid="bib19">Gu et al., 2020</xref>).</p></sec><sec id="s4-2-8"><title>SARS-CoV-2 sequencing</title><p>For SARS-CoV-2 genome sequencing, viral RNA was processed as described previously (<xref ref-type="bibr" rid="bib2">Agerer et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Popa et al., 2020</xref>). Briefly, viral RNA was reverse-transcribed with Superscript IV reverse transcriptase (Thermo Fisher Scientific) and viral sequences were amplified with modified primer pools (<xref ref-type="bibr" rid="bib27">Itokawa et al., 2020</xref>). PCR reactions were pooled and processed for high-throughput sequencing. Amplicons were cleaned up with AMPure XP beads (Beckman Coulter) with a 1:1 ratio. Amplicon concentrations and size distribution were assessed with the Qubit Fluorometric Quantitation system (Life Technologies), and the 2100 Bioanalyzer system (Agilent). Amplicon concentrations were normalized, and sequencing libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs) according to the manufacturer’s instructions. Library concentrations and size distribution were again assessed as indicated previously and pooled into equimolar amounts for sequencing. Sequencing was carried out on the NovaSeq 6000 platform (Illumina) on a SP flow cell with a read length of 2 × 250 bp in paired-end mode at the Biomedical Sequencing Facility (BSF) of the Medical University of Vienna and CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences). Following demultiplexing, FASTQ files were quality controlled using FastQC (v.0.11.8). Trimming of adapter sequences was performed with BBDUK from the BBtools suite (<ext-link ext-link-type="uri" xlink:href="http://jgi.doe.gov/data-and-tools/bbtools">http://jgi.doe.gov/data-and-tools/bbtools</ext-link>). Overlapping read sequences within a pair were corrected for using BBMERGE function from BBTools. Read pairs were mapped on the combined Hg38 and SARS-CoV-2 genome (GenBank: <ext-link ext-link-type="uri" xlink:href="https://stm.sciencemag.org/lookup/external-ref?link_type=GEN&amp;access_num=MN908947.3&amp;atom=%2Fscitransmed%2F12%2F573%2Feabe2555.atom">MN908947.3;</ext-link> RefSeq: NC_045512.2) using the BWA-MEM software package with a minimal seed length of 17 (v0.7.17) (<xref ref-type="bibr" rid="bib34">Li and Durbin, 2009</xref>). Only reads mapping uniquely to the SARS-CoV-2 viral genome were retained. Primer sequences were removed after mapping by masking with iVar (<xref ref-type="bibr" rid="bib18">Grubaugh et al., 2019</xref>). From the viral reads BAM (binary alignment map) file, the consensus FASTA file was generated using Samtools (v1.9) (<xref ref-type="bibr" rid="bib35">Li et al., 2009</xref>), mpileup, Bcftools (v 1.9) (<xref ref-type="bibr" rid="bib35">Li et al., 2009</xref>), and SEQTK (<ext-link ext-link-type="uri" xlink:href="https://github.com/lh3/seqtk">https://github.com/lh3/seqtk</ext-link>, <xref ref-type="bibr" rid="bib38">Li, 2021</xref>). For calling low-frequency variants, the viral read alignment file was realigned using the Viterbi method provided by LoFreq (v2.1.2) (<xref ref-type="bibr" rid="bib74">Wilm et al., 2012</xref>). After adding InDel qualities, low-frequency variants were called using LoFreq. Variant filtering was performed with LoFreq and Bcftools (v1.9) (<xref ref-type="bibr" rid="bib36">Li, 2011</xref>). Only variants with a minimum coverage of 75 reads, a minimum phred value of 90, and indels (insertions and deletions) with an HRUN (homopolymer length on the 3' of the variant) below 4 were considered. Based on control experiments described earlier (<xref ref-type="bibr" rid="bib2">Agerer et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Popa et al., 2020</xref>), all analyses were performed on variants with a minimum alternative frequency of 0.02. Annotations of the variants were performed with SnpEff (v4.3) (<xref ref-type="bibr" rid="bib11">Cingolani et al., 2012b</xref>) and SnpSift (v4.3) (<xref ref-type="bibr" rid="bib10">Cingolani et al., 2012a</xref>). Sequencing data of each sequenced passage were deposited at the European Nucleotide Archive (ENA; <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena">https://www.ebi.ac.uk/ena</ext-link>) under project accession PRJEB46926.</p></sec><sec id="s4-2-9"><title>Flow cytometry</title><p>For surface staining, single-cell suspensions were treated with TruStain fcX (anti-mouse CD16/32; BioLegend) and Fixable Viability Dye eFluor 780 (eBioscience) according to the manufacturer’s instructions. Subsequently, fluorescently labeled antibodies were added to cells and incubated for 20 min at 4°C. Cells were then washed and fixed for 30 min at room temperature using the Fixation Medium of the Fix and Perm Cell Fixation and Permeabilization Kit (Nordic-MUbio). Stained and fixed cell suspensions were analyzed using an LSRFortessa (BD Biosciences). A flow cytometry gating strategy example (infected mouse lung) can be found in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. After gating for single/live/CD45<sup>+</sup> cells (leukocytes), the following marker combinations have been used to identify the following cell types: lung: alveolar macrophages (AMs): CD11c<sup>+</sup>/MERTK<sup>+</sup>; neutrophils: non-AMs/CD11b<sup>+</sup>/Ly6g<sup>+</sup>; monocytes (Ly6c<sup>+</sup> and Ly6c<sup>-</sup>): non-AMs/non-neutrophils/CD11b<sup>+</sup>/CD115<sup>+</sup>; NK cells: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/NK1.1<sup>+</sup>/CD19<sup>-</sup>; B cells: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/CD19<sup>+</sup>/NK1.1<sup>-</sup>; T helper cells: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/CD19<sup>-</sup>/NK1.1<sup>-</sup>/CD3<sup>+</sup> or MHCII<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>-</sup>; cytotoxic T cells: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/CD19<sup>-</sup>/NK1.1<sup>-</sup>/CD3<sup>+</sup> or MHCII<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>-</sup>; pDCs: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/CD19<sup>-</sup>/NK1.1<sup>-</sup>/CD3<sup>+</sup> or MHCII<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>-</sup>/CD11c<sup>+</sup>/BST2<sup>+</sup>; cDCs: Ly6g<sup>-</sup> or MERTK<sup>-</sup>/CD19<sup>-</sup>/NK1.1<sup>-</sup>/CD3<sup>+</sup> or MHCII<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>-</sup>/BST2<sup>-</sup>/CD11c<sup>+</sup>; blood: neutrophils: CD3<sup>-</sup> or CD19<sup>-</sup>/CD11b<sup>+</sup>/Ly6g<sup>+</sup>; monocytes (Ly6c<sup>+</sup> and Ly6c<sup>-</sup>): CD3<sup>-</sup> or CD19<sup>-</sup>/Ly6g<sup>-</sup>/CD115<sup>+</sup>/CD11b<sup>+</sup>; B cells: CD19<sup>+</sup>/CD3<sup>-</sup>; T helper cells: CD19<sup>-</sup>/CD3<sup>+</sup>/NK1.1<sup>-</sup>/CD4<sup>+</sup>/CD8<sup>-</sup>; cytotoxic T cells: CD19<sup>-</sup>/CD3<sup>+</sup>/NK1.1<sup>-</sup>/CD8<sup>+</sup>/CD4<sup>-</sup>; NK cells: CD19<sup>-</sup>/CD3<sup>-</sup>/NK1.1<sup>+</sup>; pDCs: CD19<sup>-</sup>/CD3<sup>-</sup>/NK1.1<sup>-</sup>/CD11c<sup>+</sup>/BST2<sup>+</sup>;.</p><p>Data were analyzed using FlowJo software (FlowJo LLC) version 10.7. The fluorescently labeled anti-mouse antibodies (all obtained from BioLegend unless specifically indicated) listed in the Key resources table were used throughout this study.</p></sec><sec id="s4-2-10"><title>Plasma cytokine analysis</title><p>Plasma cytokine levels were analyzed using the LEGENDplex MU Macrophage/Microglia and Th Cytokine (V02) panels (BioLegend) according to the manufacturer’s instructions and using an LSRFortessa. Before flow cytometry analysis, samples were fixed using Fixation Medium of the Fix and Perm Cell Fixation and Permeabilization Kit (Nordic-MUbio).</p></sec><sec id="s4-2-11"><title>Analysis of SARS-CoV-2 Spike protein-specific antibodies</title><p>SARS-CoV-2 Spike-specific antibodies were detected by ELISA based on modified, previously described methodologies (<xref ref-type="bibr" rid="bib60">Starkl et al., 2020</xref>). Briefly, Nunc MaxiSorp flat-bottom plates (Thermo Fisher) were coated overnight at 4°C with 50 µl of purified recombinant SARS-CoV-2 Spike protein ectodomain (<xref ref-type="bibr" rid="bib29">Klausberger et al., 2021</xref>) (produced in CHO-K1 cells), 2 µg/ml in PBS. After washing 3× with PBS 0.05% Tween-20 (Sigma), plates were blocked by incubation with 100 µl of PBS 1% BSA for at least 2 hr at room temperature. Next, plates were washed 3×, followed by incubation with 50 µl of plasma diluted 1:50, 1:200, and 1:800 (for analysis of IgGs) or 1:40 (for analysis of IgA) for 2 hr at 37°C. After another three washing steps, 50 µl biotinylated detection antibodies specific of mouse IgG1 (clone A85-1; BD Pharmingen), IgG2b (clone R12-3; BD Pharmingen), or IgA (polyclonal; Southern Biotech; all diluted 1:1000 in PBS 1% BSA) were added, followed by incubation for 1 hr at room temperature. Plates were then washed again 3× and incubated with 50 µl of horseradish peroxidase-conjugated streptavidin (BD Pharmingen; 1:500 in PBS 1% BSA) for 20 min at room temperature. Finally, plates were washed 5× and detection was performed using the supersensitive TMB liquid substrate (Sigma) and measurement of (after stopping the reaction by addition of 50 µl 2N H<sub>2</sub>SO<sub>4</sub>) absorbance at 450 nm (620 nm reference) on a Sunrise microplate reader (Tecan). IgG titers were calculated by plotting the plasma dilution that gave half-maximal signal of a reference plasma (a plasma pool obtained from mice 14 days after infection with maVie16).</p></sec><sec id="s4-2-12"><title>Histopathological analysis</title><p>Lung samples were fixed in 7.5% formalin, embedded in paraffin, cut into 5-µm-thick sections, followed by staining with hematoxylin and eosin or Toluidine Blue. For staining of viral nucleocapsid protein, embedded samples were deparaffinized by immersion in xylene and rehydrated in graded ethanol. After blocking of endogenous peroxidase with 3% H<sub>2</sub>O<sub>2</sub> in PBS for 10 min at room temperature, tissue sections were first subjected to antigen retrieval using Antigen Unmasking Solution (Vector Labs) for 10 min and then incubated with TRIS-buffered saline containing 0.01% Tween (TBST) and 5% goat serum for 10 min at room temperature. Afterwards, slides were incubated overnight at 4°C with SARS Nucleocapsid Protein Antibody (Novus Biologicals) 1:1000 in TBST 5% goat serum. Subsequently, histological slides were washed with TBST and incubated for 30 min with biotinylated goat anti-rabbit IgG (Vector Labs) 1:200 in TBST 5% goat serum at room temperature. After washing with TBST, tissue sections were processed using the Vectastain ABC kit (Vector Labs) and DAB Substrate kit (Vector Labs) according to the manufacturer’s instructions. Tissue sections were finally stained with hematoxylin solution (Mayer’s, Sigma-Aldrich), dehydrated, and coverslipped. Histopathological scoring was performed in a blinded fashion by a trained pathologist using the following parameters: alveolar collapse, intra-alveolar exudate, alveolar septal thickening, pneumocyte proliferation, bronchiolar epithelial alteration, bronchitis, peribronchiolar inflammation, interstitial and perivascular infiltrate, and interstitial fibrosis (0 = none, 1 = mild/focal/few, 2 = severe/diffuse).</p></sec><sec id="s4-2-13"><title>Protein modeling</title><p>A comparative model of mACE2 was created using the Swiss Modeller (<xref ref-type="bibr" rid="bib71">Waterhouse et al., 2018</xref>), based on the cryoEM structure of hACE2 in complex with BOAT1 (PDB entry 6m18) (<xref ref-type="bibr" rid="bib77">Yan et al., 2020</xref>). Sequence identity was at 82%, and a model with an overall QMEAN score of –1.28 was obtained. The model superimposed to a previous model of the trimeric Spike with hACE2 (<ext-link ext-link-type="uri" xlink:href="https://covid.molssi.org//models/#spike-protein-in-complex-with-human-ace2-ace2-spike-binding">https://covid.molssi.org//models/#spike-protein-in-complex-with-human-ace2-ace2-spike-binding</ext-link>) to obtain an initial model of the Spike mACE2 complex (<xref ref-type="bibr" rid="bib7">Capraz et al., 2021</xref>). All proteins were fully glycosylated following our previously described protocols (<xref ref-type="bibr" rid="bib66">Turupcu and Oostenbrink, 2017</xref>). Visualization of the maVie16 mutations in Spike was subsequently created using the mutagenesis wizard in PyMOL (<xref ref-type="bibr" rid="bib58">Schrodinger, 2015</xref>).</p></sec><sec id="s4-2-14"><title>In vivo treatment with recombinant mACE2</title><p>rms ACE2 (amino acids 1–740) was produced in CHO cells and purified as described (<xref ref-type="bibr" rid="bib47">Monteil et al., 2020</xref>). To test in vivo ACE2 interference, mice received daily intranasal treatments with 100 µg rmsACE2 (APEIRON Biologics) or the respective dilution of vehicle. Upon prophylactic treatment, the first dose was given as a mix with maVie16 in 50 µl. All remaining doses were administered in 40 µl endotoxin-free PBS (Gibco) to isoflurane anesthetized animals. Intranasal administration to anesthetized mice is an established method that allows administration of compounds to the lower airways via inhalation due to the anesthesia-related low breathing rate and, hence, deep breaths.</p></sec><sec id="s4-2-15"><title>In vivo cytokine depletion</title><p>For in vivo depletion of IFNγ and TNF, mice were intraperitoneally injected on days 1 and 3 after maVie16 infection with 200 µl endotoxin-free PBS (Gibco) containing either 500 µg rat anti-mouse IFNγ (clone XMG1.2) and 500 µg rat anti-mouse TNF (clone XT22) or 500 µg rat IgG1 isotype control (clone GL113; specific for ß-galactosidase) obtained from Polpharma Biologics.</p></sec><sec id="s4-2-16"><title>Statistical analysis</title><p>Sample size estimation was mainly based on our experience from influenza infection experiments and was performed with R 3.5.1 using relative body weight changes as the main parameter. <italic>t</italic>-test power was calculated using the power.t.test function (‘stats’ R package). Experimental replicates are always biological replicates. Technical replicates were performed for qPCR data and ELISA data, which are measured in quadruplicates. Statistical analysis was performed using GraphPad Prism 9.1 (GraphPad Software). Details regarding statistical analyses of experiments can be found in the respective figure legends. p-Values ≤ 0.05 were considered statistically significant.</p></sec></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is an employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients</p></fn><fn fn-type="COI-statement" id="conf4"><p>declares a conflict of interest as a founder and shareholder of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients.(patent #WO2021191436A1)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation, Supervision</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Formal analysis</p></fn><fn fn-type="con" id="con14"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con15"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con16"><p>Investigation</p></fn><fn fn-type="con" id="con17"><p>Investigation</p></fn><fn fn-type="con" id="con18"><p>Supervision</p></fn><fn fn-type="con" id="con19"><p>Supervision</p></fn><fn fn-type="con" id="con20"><p>Supervision</p></fn><fn fn-type="con" id="con21"><p>Supervision</p></fn><fn fn-type="con" id="con22"><p>Formal analysis, Supervision, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con23"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con24"><p>Conceptualization, Funding acquisition, Investigation, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experiments involving SARS-CoV-2 or its derivatives were performed in Biosafety Level 3 (BSL-3) facilities at the Medical University of Vienna and performed according to the ethical guidelines and after approval by the institutional review board of the Austrian Ministry of Sciences (BMBWF-2020-0.253.770) and in accordance with the directives of the EU.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-74623-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>maVie16 SARS-CoV-2 genome sequence will be published on: <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena">https://www.ebi.ac.uk/ena</ext-link> Project accession: PRJEB46926.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences</collab></person-group><source>European Nucleotide Archive</source><year iso-8601-date="2021">2021</year><data-title>Exploring COVID-19 disease, immunity and therapeutic options in mice using maVie16, a host-adapted SARS-CoV-2</data-title><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB46926">PRJEB46926</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the animal care takers and veterinarians at the animal facility of the Medical University of Vienna for expert help. Dr. Reinhard Grabherr, University of Natural Resources and Life Sciences, Vienna, Austria, kindly provided us with recombinant Spike protein. We thank Hans-Christian Theussl at the Institute for Molecular Biotechnology, Vienna, Austria, for support. We appreciate support by the flow cytometry core facility of the Medical University of Vienna and the Biomedical Sequencing Facility (BSF) jointly run by the Medical University of Vienna and CeMM. SK was supported by the Austrian Science Fund FWF within the special research programs Immunothrombosis (F54-10) and Chromatin Landscapes (F61-04). RG received funding by the Austrian Science Fund FWF (ZK57-B28), and PS acknowledges funding by the Austrian Science Fund (FWF) (P31113-B30). AOR and HS were supported by the FWF (P 34253-B). BA was supported by the Austrian Science Fund (FWF) DK W1212. JMP and the research leading to these results has received funding from the T von Zastrow foundation, the FWF Wittgenstein award (Z271-B19), the Austrian Academy of Sciences, the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 101005026, and the Canada 150 Research Chairs Program F18-01336 as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>LE</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Heise</surname><given-names>MT</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication</article-title><source>MBio</source><volume>12</volume><elocation-id>e03149-20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.03149-20</pub-id><pub-id pub-id-type="pmid">33727353</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agerer</surname><given-names>B</given-names></name><name><surname>Koblischke</surname><given-names>M</given-names></name><name><surname>Gudipati</surname><given-names>V</given-names></name><name><surname>Montaño-Gutierrez</surname><given-names>LF</given-names></name><name><surname>Smyth</surname><given-names>M</given-names></name><name><surname>Popa</surname><given-names>A</given-names></name><name><surname>Genger</surname><given-names>JW</given-names></name><name><surname>Endler</surname><given-names>L</given-names></name><name><surname>Florian</surname><given-names>DM</given-names></name><name><surname>Mühlgrabner</surname><given-names>V</given-names></name><name><surname>Graninger</surname><given-names>M</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Husa</surname><given-names>AM</given-names></name><name><surname>Shaw</surname><given-names>LE</given-names></name><name><surname>Lercher</surname><given-names>A</given-names></name><name><surname>Gattinger</surname><given-names>P</given-names></name><name><surname>Torralba-Gombau</surname><given-names>R</given-names></name><name><surname>Trapin</surname><given-names>D</given-names></name><name><surname>Penz</surname><given-names>T</given-names></name><name><surname>Barreca</surname><given-names>D</given-names></name><name><surname>Fae</surname><given-names>I</given-names></name><name><surname>Wenda</surname><given-names>S</given-names></name><name><surname>Traugott</surname><given-names>M</given-names></name><name><surname>Walder</surname><given-names>G</given-names></name><name><surname>Pickl</surname><given-names>WF</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Allerberger</surname><given-names>F</given-names></name><name><surname>Stockinger</surname><given-names>H</given-names></name><name><surname>Puchhammer-Stöckl</surname><given-names>E</given-names></name><name><surname>Weninger</surname><given-names>W</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Hoepler</surname><given-names>W</given-names></name><name><surname>Pawelka</surname><given-names>E</given-names></name><name><surname>Zoufaly</surname><given-names>A</given-names></name><name><surname>Valenta</surname><given-names>R</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Paster</surname><given-names>W</given-names></name><name><surname>Geyeregger</surname><given-names>R</given-names></name><name><surname>Farlik</surname><given-names>M</given-names></name><name><surname>Halbritter</surname><given-names>F</given-names></name><name><surname>Huppa</surname><given-names>JB</given-names></name><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses</article-title><source>Science Immunology</source><volume>6</volume><elocation-id>eabg6461</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abg6461</pub-id><pub-id pub-id-type="pmid">33664060</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baazim</surname><given-names>H</given-names></name><name><surname>Antonio-Herrera</surname><given-names>L</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The interplay of immunology and cachexia in infection and cancer</article-title><source>Nature Reviews. Immunology</source><volume>21</volume><elocation-id>624</elocation-id><pub-id pub-id-type="doi">10.1038/s41577-021-00624-w</pub-id><pub-id pub-id-type="pmid">34608281</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Björkström</surname><given-names>NK</given-names></name><name><surname>Strunz</surname><given-names>B</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Natural killer cells in antiviral immunity</article-title><source>Nature Reviews. Immunology</source><volume>10</volume><elocation-id>558</elocation-id><pub-id pub-id-type="doi">10.1038/s41577-021-00558-3</pub-id><pub-id pub-id-type="pmid">34117484</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Lavine</surname><given-names>CL</given-names></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Anand</surname><given-names>K</given-names></name><name><surname>Tong</surname><given-names>P</given-names></name><name><surname>Gautam</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Sterling</surname><given-names>SM</given-names></name><name><surname>Walsh</surname><given-names>RM</given-names></name><name><surname>Rits-Volloch</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wesemann</surname><given-names>DR</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants</article-title><source>Science</source><volume>373</volume><fpage>642</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1126/science.abi9745</pub-id><pub-id pub-id-type="pmid">34168070</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantuti-Castelvetri</surname><given-names>L</given-names></name><name><surname>Ojha</surname><given-names>R</given-names></name><name><surname>Pedro</surname><given-names>LD</given-names></name><name><surname>Djannatian</surname><given-names>M</given-names></name><name><surname>Franz</surname><given-names>J</given-names></name><name><surname>Kuivanen</surname><given-names>S</given-names></name><name><surname>van der Meer</surname><given-names>F</given-names></name><name><surname>Kallio</surname><given-names>K</given-names></name><name><surname>Kaya</surname><given-names>T</given-names></name><name><surname>Anastasina</surname><given-names>M</given-names></name><name><surname>Smura</surname><given-names>T</given-names></name><name><surname>Levanov</surname><given-names>L</given-names></name><name><surname>Szirovicza</surname><given-names>L</given-names></name><name><surname>Tobi</surname><given-names>A</given-names></name><name><surname>Kallio-Kokko</surname><given-names>H</given-names></name><name><surname>Österlund</surname><given-names>P</given-names></name><name><surname>Joensuu</surname><given-names>M</given-names></name><name><surname>Meunier</surname><given-names>FA</given-names></name><name><surname>Butcher</surname><given-names>SJ</given-names></name><name><surname>Winkler</surname><given-names>MS</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Helenius</surname><given-names>A</given-names></name><name><surname>Gokce</surname><given-names>O</given-names></name><name><surname>Teesalu</surname><given-names>T</given-names></name><name><surname>Hepojoki</surname><given-names>J</given-names></name><name><surname>Vapalahti</surname><given-names>O</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Balistreri</surname><given-names>G</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title><source>Science</source><volume>370</volume><fpage>856</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1126/science.abd2985</pub-id><pub-id pub-id-type="pmid">33082293</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capraz</surname><given-names>T</given-names></name><name><surname>Kienzl</surname><given-names>NF</given-names></name><name><surname>Laurent</surname><given-names>E</given-names></name><name><surname>Perthold</surname><given-names>JW</given-names></name><name><surname>Föderl-Höbenreich</surname><given-names>E</given-names></name><name><surname>Grünwald-Gruber</surname><given-names>C</given-names></name><name><surname>Maresch</surname><given-names>D</given-names></name><name><surname>Monteil</surname><given-names>V</given-names></name><name><surname>Niederhöfer</surname><given-names>J</given-names></name><name><surname>Wirnsberger</surname><given-names>G</given-names></name><name><surname>Mirazimi</surname><given-names>A</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><name><surname>Mach</surname><given-names>L</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Oostenbrink</surname><given-names>C</given-names></name><name><surname>Stadlmann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor</article-title><source>eLife</source><volume>10</volume><elocation-id>e73641</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.73641</pub-id><pub-id pub-id-type="pmid">34927585</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>2620</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><pub-id pub-id-type="pmid">32217835</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>MH</given-names></name><name><surname>Krieger</surname><given-names>JM</given-names></name><name><surname>Kaynak</surname><given-names>B</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Bahar</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-Based Computational Assessment</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.01.10.426143</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>VM</given-names></name><name><surname>Coon</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Land</surname><given-names>SJ</given-names></name><name><surname>Ruden</surname><given-names>DM</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Using <italic>Drosophila melanogaster</italic> as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift</article-title><source>Frontiers in Genetics</source><volume>3</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2012.00035</pub-id><pub-id pub-id-type="pmid">22435069</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname><given-names>P</given-names></name><name><surname>Platts</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Coon</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Land</surname><given-names>SJ</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Ruden</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff</article-title><source>Fly</source><volume>6</volume><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.4161/fly.19695</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Oudit</surname><given-names>GY</given-names></name><name><surname>Yagil</surname><given-names>C</given-names></name><name><surname>Kozieradzki</surname><given-names>I</given-names></name><name><surname>Scanga</surname><given-names>SE</given-names></name><name><surname>Oliveira-dos-Santos</surname><given-names>AJ</given-names></name><name><surname>da Costa</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Scholey</surname><given-names>J</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Manoukian</surname><given-names>AS</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name><name><surname>Backx</surname><given-names>PH</given-names></name><name><surname>Yagil</surname><given-names>Y</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title><source>Nature</source><volume>417</volume><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/nature00786</pub-id><pub-id pub-id-type="pmid">12075344</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>JL</given-names></name><name><surname>Simonetti</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>K-E</given-names></name><name><surname>Williamson</surname><given-names>MK</given-names></name><name><surname>Antón-Plágaro</surname><given-names>C</given-names></name><name><surname>Shoemark</surname><given-names>DK</given-names></name><name><surname>Simón-Gracia</surname><given-names>L</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Hollandi</surname><given-names>R</given-names></name><name><surname>Greber</surname><given-names>UF</given-names></name><name><surname>Horvath</surname><given-names>P</given-names></name><name><surname>Sessions</surname><given-names>RB</given-names></name><name><surname>Helenius</surname><given-names>A</given-names></name><name><surname>Hiscox</surname><given-names>JA</given-names></name><name><surname>Teesalu</surname><given-names>T</given-names></name><name><surname>Matthews</surname><given-names>DA</given-names></name><name><surname>Davidson</surname><given-names>AD</given-names></name><name><surname>Collins</surname><given-names>BM</given-names></name><name><surname>Cullen</surname><given-names>PJ</given-names></name><name><surname>Yamauchi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neuropilin-1 is a host factor for SARS-CoV-2 infection</article-title><source>Science</source><volume>370</volume><fpage>861</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1126/science.abd3072</pub-id><pub-id pub-id-type="pmid">33082294</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damas</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>GM</given-names></name><name><surname>Keough</surname><given-names>KC</given-names></name><name><surname>Painter</surname><given-names>CA</given-names></name><name><surname>Persky</surname><given-names>NS</given-names></name><name><surname>Corbo</surname><given-names>M</given-names></name><name><surname>Hiller</surname><given-names>M</given-names></name><name><surname>Koepfli</surname><given-names>KP</given-names></name><name><surname>Pfenning</surname><given-names>AR</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Genereux</surname><given-names>DP</given-names></name><name><surname>Swofford</surname><given-names>R</given-names></name><name><surname>Pollard</surname><given-names>KS</given-names></name><name><surname>Ryder</surname><given-names>OA</given-names></name><name><surname>Nweeia</surname><given-names>MT</given-names></name><name><surname>Lindblad-Toh</surname><given-names>K</given-names></name><name><surname>Teeling</surname><given-names>EC</given-names></name><name><surname>Karlsson</surname><given-names>EK</given-names></name><name><surname>Lewin</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates</article-title><source>PNAS</source><volume>117</volume><fpage>22311</fpage><lpage>22322</lpage><pub-id pub-id-type="doi">10.1073/pnas.2010146117</pub-id><pub-id pub-id-type="pmid">32826334</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Yount</surname><given-names>BL</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Adams</surname><given-names>LE</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Bryant</surname><given-names>MD</given-names></name><name><surname>Choong</surname><given-names>IC</given-names></name><name><surname>Glenn</surname><given-names>JS</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures</article-title><source>Nature</source><volume>586</volume><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2708-8</pub-id><pub-id pub-id-type="pmid">32854108</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Garami</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>AA</given-names></name><name><surname>Romanovsky</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Fever and hypothermia in systemic inflammation</chapter-title><person-group person-group-type="editor"><name><surname>Garami</surname><given-names>A</given-names></name></person-group><source>Handbook of Clinical Neurology</source><publisher-name>Meta</publisher-name><fpage>565</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-64074-1.00034-3</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>RA</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L</given-names></name><name><surname>Markov</surname><given-names>NS</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Querrey</surname><given-names>M</given-names></name><name><surname>Guzman</surname><given-names>ER</given-names></name><name><surname>Abbott</surname><given-names>DA</given-names></name><name><surname>Donnelly</surname><given-names>HK</given-names></name><name><surname>Donayre</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>IA</given-names></name><name><surname>Klug</surname><given-names>ZM</given-names></name><name><surname>Borkowski</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Kihshen</surname><given-names>H</given-names></name><name><surname>Politanska</surname><given-names>Y</given-names></name><name><surname>Sichizya</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Lomasney</surname><given-names>JW</given-names></name><name><surname>Argento</surname><given-names>AC</given-names></name><name><surname>Kruser</surname><given-names>JM</given-names></name><name><surname>Malsin</surname><given-names>ES</given-names></name><name><surname>Pickens</surname><given-names>CO</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Walter</surname><given-names>JM</given-names></name><name><surname>Pawlowski</surname><given-names>AE</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Nannapaneni</surname><given-names>P</given-names></name><name><surname>Abdala-Valencia</surname><given-names>H</given-names></name><name><surname>Bharat</surname><given-names>A</given-names></name><name><surname>Gottardi</surname><given-names>CJ</given-names></name><name><surname>Budinger</surname><given-names>GRS</given-names></name><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><collab>NU SCRIPT Study Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia</article-title><source>Nature</source><volume>590</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03148-w</pub-id><pub-id pub-id-type="pmid">33429418</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Gangavarapu</surname><given-names>K</given-names></name><name><surname>Quick</surname><given-names>J</given-names></name><name><surname>Matteson</surname><given-names>NL</given-names></name><name><surname>De Jesus</surname><given-names>JG</given-names></name><name><surname>Main</surname><given-names>BJ</given-names></name><name><surname>Tan</surname><given-names>AL</given-names></name><name><surname>Paul</surname><given-names>LM</given-names></name><name><surname>Brackney</surname><given-names>DE</given-names></name><name><surname>Grewal</surname><given-names>S</given-names></name><name><surname>Gurfield</surname><given-names>N</given-names></name><name><surname>Van Rompay</surname><given-names>KKA</given-names></name><name><surname>Isern</surname><given-names>S</given-names></name><name><surname>Michael</surname><given-names>SF</given-names></name><name><surname>Coffey</surname><given-names>LL</given-names></name><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Andersen</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1618-7</pub-id><pub-id pub-id-type="pmid">30621750</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>Y-Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X-F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>N-N</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>D-Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>C-F</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy</article-title><source>Science</source><volume>369</volume><fpage>1603</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1126/science.abc4730</pub-id><pub-id pub-id-type="pmid">32732280</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hassler</surname><given-names>L</given-names></name><name><surname>Wysocki</surname><given-names>J</given-names></name><name><surname>Gelarden</surname><given-names>I</given-names></name><name><surname>Tomatsidou</surname><given-names>A</given-names></name><name><surname>Gula</surname><given-names>H</given-names></name><name><surname>Nicoleascu</surname><given-names>V</given-names></name><name><surname>Randall</surname><given-names>G</given-names></name><name><surname>Henkin</surname><given-names>J</given-names></name><name><surname>Yeldandi</surname><given-names>A</given-names></name><name><surname>Batlle</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A Novel Soluble ACE2 Protein Totally Protects from Lethal Disease Caused by SARS-CoV-2 Infection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.03.12.435191</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Arimori</surname><given-names>T</given-names></name><name><surname>Ikemura</surname><given-names>N</given-names></name><name><surname>Mihara</surname><given-names>E</given-names></name><name><surname>Kirita</surname><given-names>Y</given-names></name><name><surname>Ohgitani</surname><given-names>E</given-names></name><name><surname>Mazda</surname><given-names>O</given-names></name><name><surname>Motooka</surname><given-names>D</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Sugihara</surname><given-names>F</given-names></name><name><surname>Matsuura</surname><given-names>Y</given-names></name><name><surname>Matoba</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>J</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3802</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24013-y</pub-id><pub-id pub-id-type="pmid">34155214</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hikmet</surname><given-names>F</given-names></name><name><surname>Mear</surname><given-names>L</given-names></name><name><surname>Edvinsson</surname><given-names>A</given-names></name><name><surname>Micke</surname><given-names>P</given-names></name><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The protein expression profile of ACE2 in human tissues</article-title><source>Molecular Systems Biology</source><volume>16</volume><elocation-id>e9610</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20209610</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kruger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pohlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>JE</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Damask</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Roberts</surname><given-names>GHL</given-names></name><name><surname>Justice</surname><given-names>AE</given-names></name><name><surname>Banerjee</surname><given-names>N</given-names></name><name><surname>Coignet</surname><given-names>MV</given-names></name><name><surname>Yadav</surname><given-names>A</given-names></name><name><surname>Leader</surname><given-names>JB</given-names></name><name><surname>Marcketta</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Lanche</surname><given-names>R</given-names></name><name><surname>Maxwell</surname><given-names>E</given-names></name><name><surname>Knight</surname><given-names>SC</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Guturu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Baltzell</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Common Genetic Variants Identify Targets for COVID-19 and Individuals at High Risk of Severe Disease</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.14.20248176</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hui</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>YJ</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice</article-title><source>EBioMedicine</source><volume>67</volume><elocation-id>103381</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103381</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Meir</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Alfajaro</surname><given-names>MM</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Ring</surname><given-names>A</given-names></name><name><surname>Wilen</surname><given-names>CB</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20201241</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itokawa</surname><given-names>K</given-names></name><name><surname>Sekizuka</surname><given-names>T</given-names></name><name><surname>Hashino</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>R</given-names></name><name><surname>Kuroda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0239403</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0239403</pub-id><pub-id pub-id-type="pmid">32946527</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Banoth</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Schreiner</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes</article-title><source>Cell</source><volume>184</volume><fpage>149</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausberger</surname><given-names>M</given-names></name><name><surname>Duerkop</surname><given-names>M</given-names></name><name><surname>Haslacher</surname><given-names>H</given-names></name><name><surname>Wozniak-Knopp</surname><given-names>G</given-names></name><name><surname>Cserjan-Puschmann</surname><given-names>M</given-names></name><name><surname>Perkmann</surname><given-names>T</given-names></name><name><surname>Lingg</surname><given-names>N</given-names></name><name><surname>Aguilar</surname><given-names>PP</given-names></name><name><surname>Laurent</surname><given-names>E</given-names></name><name><surname>De Vos</surname><given-names>J</given-names></name><name><surname>Hofner</surname><given-names>M</given-names></name><name><surname>Holzer</surname><given-names>B</given-names></name><name><surname>Stadler</surname><given-names>M</given-names></name><name><surname>Manhart</surname><given-names>G</given-names></name><name><surname>Vierlinger</surname><given-names>K</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Milchram</surname><given-names>L</given-names></name><name><surname>Gludovacz</surname><given-names>E</given-names></name><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Köppl</surname><given-names>C</given-names></name><name><surname>Tauer</surname><given-names>C</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Maresch</surname><given-names>D</given-names></name><name><surname>Grünwald-Gruber</surname><given-names>C</given-names></name><name><surname>Strobl</surname><given-names>F</given-names></name><name><surname>Satzer</surname><given-names>P</given-names></name><name><surname>Stadlmayr</surname><given-names>G</given-names></name><name><surname>Vavra</surname><given-names>U</given-names></name><name><surname>Huber</surname><given-names>J</given-names></name><name><surname>Wahrmann</surname><given-names>M</given-names></name><name><surname>Eskandary</surname><given-names>F</given-names></name><name><surname>Breyer</surname><given-names>MK</given-names></name><name><surname>Sieghart</surname><given-names>D</given-names></name><name><surname>Quehenberger</surname><given-names>P</given-names></name><name><surname>Leitner</surname><given-names>G</given-names></name><name><surname>Strassl</surname><given-names>R</given-names></name><name><surname>Egger</surname><given-names>AE</given-names></name><name><surname>Irsara</surname><given-names>C</given-names></name><name><surname>Griesmacher</surname><given-names>A</given-names></name><name><surname>Hoermann</surname><given-names>G</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Bellmann-Weiler</surname><given-names>R</given-names></name><name><surname>Loeffler-Ragg</surname><given-names>J</given-names></name><name><surname>Borth</surname><given-names>N</given-names></name><name><surname>Strasser</surname><given-names>R</given-names></name><name><surname>Jungbauer</surname><given-names>A</given-names></name><name><surname>Hahn</surname><given-names>R</given-names></name><name><surname>Mairhofer</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>B</given-names></name><name><surname>Binder</surname><given-names>NB</given-names></name><name><surname>Striedner</surname><given-names>G</given-names></name><name><surname>Mach</surname><given-names>L</given-names></name><name><surname>Weinhäusel</surname><given-names>A</given-names></name><name><surname>Dieplinger</surname><given-names>B</given-names></name><name><surname>Grebien</surname><given-names>F</given-names></name><name><surname>Gerner</surname><given-names>W</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Grabherr</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests</article-title><source>EBioMedicine</source><volume>67</volume><elocation-id>103348</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103348</pub-id><pub-id pub-id-type="pmid">33906067</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chappell</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Leibbrandt</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title><source>Nature Medicine</source><volume>11</volume><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1038/nm1267</pub-id><pub-id pub-id-type="pmid">16007097</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Rothan</surname><given-names>HA</given-names></name><name><surname>Natekar</surname><given-names>JP</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><name><surname>Pathak</surname><given-names>H</given-names></name><name><surname>Strate</surname><given-names>PG</given-names></name><name><surname>Arora</surname><given-names>K</given-names></name><name><surname>Brinton</surname><given-names>MA</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice</article-title><source>Viruses</source><volume>13</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.3390/v13010132</pub-id><pub-id pub-id-type="pmid">33477869</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Where did “weird” Omicron come from?</article-title><source>Science</source><volume>374</volume><elocation-id>1179</elocation-id><pub-id pub-id-type="doi">10.1126/science.acx9738</pub-id><pub-id pub-id-type="pmid">34855502</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Tse</surname><given-names>LV</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Sanders</surname><given-names>W</given-names></name><name><surname>Fritch</surname><given-names>EJ</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Moorman</surname><given-names>NJ</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice</article-title><source>Cell</source><volume>183</volume><fpage>1070</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.050</pub-id><pub-id pub-id-type="pmid">33031744</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmid">19451168</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Genome Project Data Processing</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The Sequence Alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data</article-title><source>Bioinformatics</source><volume>27</volume><fpage>2987</fpage><lpage>2993</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr509</pub-id><pub-id pub-id-type="pmid">21903627</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>R</given-names></name><name><surname>Leung</surname><given-names>KSM</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Wong</surname><given-names>JY</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>TTY</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia</article-title><source>The New England Journal of Medicine</source><volume>382</volume><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Seqtk</data-title><version designator="7c04ce7">7c04ce7</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/lh3/seqtk">https://github.com/lh3/seqtk</ext-link></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linsky</surname><given-names>TW</given-names></name><name><surname>Vergara</surname><given-names>R</given-names></name><name><surname>Codina</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>JW</given-names></name><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Hsiang</surname><given-names>T-Y</given-names></name><name><surname>Esser-Nobis</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Reneer</surname><given-names>ZB</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Priya</surname><given-names>T</given-names></name><name><surname>Mitsumoto</surname><given-names>M</given-names></name><name><surname>Pong</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>UY</given-names></name><name><surname>Mason</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Berrocal</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Clairmont</surname><given-names>NS</given-names></name><name><surname>Castellanos</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y-R</given-names></name><name><surname>Josephson-Day</surname><given-names>A</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Fuller</surname><given-names>DH</given-names></name><name><surname>Walkey</surname><given-names>CD</given-names></name><name><surname>Ross</surname><given-names>TM</given-names></name><name><surname>Swanson</surname><given-names>R</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Gale</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Blancas-Mejia</surname><given-names>LM</given-names></name><name><surname>Yen</surname><given-names>H-L</given-names></name><name><surname>Silva</surname><given-names>D-A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2</article-title><source>Science</source><volume>370</volume><fpage>1208</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1126/science.abe0075</pub-id><pub-id pub-id-type="pmid">33154107</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 cell tropism and multiorgan infection</article-title><source>Cell Discovery</source><volume>7</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1038/s41421-021-00249-2</pub-id><pub-id pub-id-type="pmid">33758165</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machacek</surname><given-names>C</given-names></name><name><surname>Supper</surname><given-names>V</given-names></name><name><surname>Leksa</surname><given-names>V</given-names></name><name><surname>Mitulovic</surname><given-names>G</given-names></name><name><surname>Spittler</surname><given-names>A</given-names></name><name><surname>Drbal</surname><given-names>K</given-names></name><name><surname>Suchanek</surname><given-names>M</given-names></name><name><surname>Ohradanova-Repic</surname><given-names>A</given-names></name><name><surname>Stockinger</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen</article-title><source>Journal of Immunology</source><volume>197</volume><fpage>2229</fpage><lpage>2238</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501878</pub-id><pub-id pub-id-type="pmid">27534550</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangalmurti</surname><given-names>N</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cytokine Storms: Understanding COVID-19</article-title><source>Immunity</source><volume>53</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.017</pub-id><pub-id pub-id-type="pmid">32610079</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Nao</surname><given-names>N</given-names></name><name><surname>Shirato</surname><given-names>K</given-names></name><name><surname>Kawase</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Takayama</surname><given-names>I</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Sekizuka</surname><given-names>T</given-names></name><name><surname>Katoh</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>F</given-names></name><name><surname>Sakata</surname><given-names>M</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Kutsuna</surname><given-names>S</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Kuroda</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kageyama</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title><source>PNAS</source><volume>117</volume><fpage>7001</fpage><lpage>7003</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCray</surname><given-names>PB</given-names></name><name><surname>Pewe</surname><given-names>L</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Manzel</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Netland</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>HP</given-names></name><name><surname>Halabi</surname><given-names>C</given-names></name><name><surname>Sigmund</surname><given-names>CD</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Kirby</surname><given-names>P</given-names></name><name><surname>Look</surname><given-names>DC</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title><source>Journal of Virology</source><volume>81</volume><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1128/JVI.02012-06</pub-id><pub-id pub-id-type="pmid">17079315</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An aberrant inflammatory response in severe COVID-19</article-title><source>Cell Host &amp; Microbe</source><volume>29</volume><fpage>1043</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.06.018</pub-id><pub-id pub-id-type="pmid">34265243</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Montagutelli</surname><given-names>X</given-names></name><name><surname>Prot</surname><given-names>M</given-names></name><name><surname>Levillayer</surname><given-names>L</given-names></name><name><surname>Salazar</surname><given-names>EB</given-names></name><name><surname>Jouvion</surname><given-names>G</given-names></name><name><surname>Conquet</surname><given-names>L</given-names></name><name><surname>Donati</surname><given-names>F</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Gambaro</surname><given-names>F</given-names></name><name><surname>Behillil</surname><given-names>S</given-names></name><name><surname>Enouf</surname><given-names>V</given-names></name><name><surname>Rousset</surname><given-names>D</given-names></name><name><surname>Jaubert</surname><given-names>J</given-names></name><name><surname>Rey</surname><given-names>F</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Simon-Loriere</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The B1.351 and P.1 Variants Extend SARS-CoV-2 Host Range to Mice</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.03.18.436013</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V</given-names></name><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Prado</surname><given-names>P</given-names></name><name><surname>Hagelkrüys</surname><given-names>A</given-names></name><name><surname>Wimmer</surname><given-names>RA</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Leopoldi</surname><given-names>A</given-names></name><name><surname>Garreta</surname><given-names>E</given-names></name><name><surname>Hurtado Del Pozo</surname><given-names>C</given-names></name><name><surname>Prosper</surname><given-names>F</given-names></name><name><surname>Romero</surname><given-names>JP</given-names></name><name><surname>Wirnsberger</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Conder</surname><given-names>R</given-names></name><name><surname>Montserrat</surname><given-names>N</given-names></name><name><surname>Mirazimi</surname><given-names>A</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2</article-title><source>Cell</source><volume>181</volume><fpage>905</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id><pub-id pub-id-type="pmid">32333836</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murgolo</surname><given-names>N</given-names></name><name><surname>Therien</surname><given-names>AG</given-names></name><name><surname>Howell</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>D</given-names></name><name><surname>Koeplinger</surname><given-names>K</given-names></name><name><surname>Lieberman</surname><given-names>LA</given-names></name><name><surname>Adam</surname><given-names>GC</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><name><surname>McKenna</surname><given-names>P</given-names></name><name><surname>Swaminathan</surname><given-names>G</given-names></name><name><surname>Hazuda</surname><given-names>DJ</given-names></name><name><surname>Olsen</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1009225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009225</pub-id><pub-id pub-id-type="pmid">33596266</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oladunni</surname><given-names>FS</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Pino</surname><given-names>PA</given-names></name><name><surname>Gonzalez</surname><given-names>O</given-names></name><name><surname>Akhter</surname><given-names>A</given-names></name><name><surname>Allué-Guardia</surname><given-names>A</given-names></name><name><surname>Olmo-Fontánez</surname><given-names>A</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Garcia-Vilanova</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Chiem</surname><given-names>K</given-names></name><name><surname>Headley</surname><given-names>C</given-names></name><name><surname>Dwivedi</surname><given-names>V</given-names></name><name><surname>Parodi</surname><given-names>LM</given-names></name><name><surname>Alfson</surname><given-names>KJ</given-names></name><name><surname>Staples</surname><given-names>HM</given-names></name><name><surname>Schami</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>JI</given-names></name><name><surname>Whigham</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>RN</given-names></name><name><surname>Gazi</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Chuba</surname><given-names>C</given-names></name><name><surname>Earley</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>OH</given-names></name><name><surname>Mdaki</surname><given-names>SD</given-names></name><name><surname>Kavelish</surname><given-names>KN</given-names></name><name><surname>Escalona</surname><given-names>R</given-names></name><name><surname>Hallam</surname><given-names>CRA</given-names></name><name><surname>Christie</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>JL</given-names></name><name><surname>Anderson</surname><given-names>TJC</given-names></name><name><surname>Carrion</surname><given-names>R</given-names></name><name><surname>Dick</surname><given-names>EJ</given-names></name><name><surname>Hall-Ursone</surname><given-names>S</given-names></name><name><surname>Schlesinger</surname><given-names>LS</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name><name><surname>Giavedoni</surname><given-names>LD</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Torrelles</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6122</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19891-7</pub-id><pub-id pub-id-type="pmid">33257679</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paranjpe</surname><given-names>I</given-names></name><name><surname>Russak</surname><given-names>AJ</given-names></name><name><surname>De Freitas</surname><given-names>JK</given-names></name><name><surname>Lala</surname><given-names>A</given-names></name><name><surname>Miotto</surname><given-names>R</given-names></name><name><surname>Vaid</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name><name><surname>Danieletto</surname><given-names>M</given-names></name><name><surname>Golden</surname><given-names>E</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Somani</surname><given-names>S</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>O’Hagan</surname><given-names>R</given-names></name><name><surname>Manna</surname><given-names>S</given-names></name><name><surname>Nangia</surname><given-names>U</given-names></name><name><surname>Jaladanki</surname><given-names>SK</given-names></name><name><surname>O’Reilly</surname><given-names>P</given-names></name><name><surname>Huckins</surname><given-names>LM</given-names></name><name><surname>Glowe</surname><given-names>P</given-names></name><name><surname>Kia</surname><given-names>A</given-names></name><name><surname>Timsina</surname><given-names>P</given-names></name><name><surname>Freeman</surname><given-names>RM</given-names></name><name><surname>Levin</surname><given-names>MA</given-names></name><name><surname>Jhang</surname><given-names>J</given-names></name><name><surname>Firpo</surname><given-names>A</given-names></name><name><surname>Kovatch</surname><given-names>P</given-names></name><name><surname>Finkelstein</surname><given-names>J</given-names></name><name><surname>Aberg</surname><given-names>JA</given-names></name><name><surname>Bagiella</surname><given-names>E</given-names></name><name><surname>Horowitz</surname><given-names>CR</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Narula</surname><given-names>J</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Charney</surname><given-names>D</given-names></name><name><surname>Reich</surname><given-names>DL</given-names></name><name><surname>Just</surname><given-names>A</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><name><surname>Charney</surname><given-names>AW</given-names></name><name><surname>Glicksberg</surname><given-names>BS</given-names></name><name><surname>Nadkarni</surname><given-names>GN</given-names></name><collab>Mount Sinai COVID Informatics Center</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City</article-title><source>BMJ Open</source><volume>10</volume><elocation-id>e040736</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-040736</pub-id><pub-id pub-id-type="pmid">33247020</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parolin</surname><given-names>C</given-names></name><name><surname>Virtuoso</surname><given-names>S</given-names></name><name><surname>Giovanetti</surname><given-names>M</given-names></name><name><surname>Angeletti</surname><given-names>S</given-names></name><name><surname>Ciccozzi</surname><given-names>M</given-names></name><name><surname>Borsetti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Animal Hosts and Experimental Models of SARS-CoV-2 Infection</article-title><source>Chemotherapy</source><volume>66</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1159/000515341</pub-id><pub-id pub-id-type="pmid">33774628</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popa</surname><given-names>A</given-names></name><name><surname>Genger</surname><given-names>JW</given-names></name><name><surname>Nicholson</surname><given-names>MD</given-names></name><name><surname>Penz</surname><given-names>T</given-names></name><name><surname>Schmid</surname><given-names>D</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Agerer</surname><given-names>B</given-names></name><name><surname>Lercher</surname><given-names>A</given-names></name><name><surname>Endler</surname><given-names>L</given-names></name><name><surname>Colaço</surname><given-names>H</given-names></name><name><surname>Smyth</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>M</given-names></name><name><surname>Grau</surname><given-names>ML</given-names></name><name><surname>Martínez-Jiménez</surname><given-names>F</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Borena</surname><given-names>W</given-names></name><name><surname>Pawelka</surname><given-names>E</given-names></name><name><surname>Keszei</surname><given-names>Z</given-names></name><name><surname>Senekowitsch</surname><given-names>M</given-names></name><name><surname>Laine</surname><given-names>J</given-names></name><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Redlberger-Fritz</surname><given-names>M</given-names></name><name><surname>Karolyi</surname><given-names>M</given-names></name><name><surname>Zoufaly</surname><given-names>A</given-names></name><name><surname>Maritschnik</surname><given-names>S</given-names></name><name><surname>Borkovec</surname><given-names>M</given-names></name><name><surname>Hufnagl</surname><given-names>P</given-names></name><name><surname>Nairz</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Wolfinger</surname><given-names>MT</given-names></name><name><surname>von Laer</surname><given-names>D</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Puchhammer-Stöckl</surname><given-names>E</given-names></name><name><surname>Allerberger</surname><given-names>F</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>573</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abe2555</pub-id><pub-id pub-id-type="pmid">33229462</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathnasinghe</surname><given-names>R</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Gillespie</surname><given-names>VL</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Uccellini</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection</article-title><source>Emerging Microbes &amp; Infections</source><volume>9</volume><fpage>2433</fpage><lpage>2445</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1838955</pub-id><pub-id pub-id-type="pmid">33073694</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>LJ</given-names></name><name><surname>Muench</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1938">1938</year><article-title>A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12</article-title><source>American Journal of Epidemiology</source><volume>27</volume><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a118408</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>JS</given-names></name><name><surname>Narasimhan</surname><given-names>M</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>McGinn</surname><given-names>T</given-names></name><name><surname>Davidson</surname><given-names>KW</given-names></name><collab>the Northwell COVID-19 Research Consortium</collab><name><surname>Barnaby</surname><given-names>DP</given-names></name><name><surname>Becker</surname><given-names>LB</given-names></name><name><surname>Chelico</surname><given-names>JD</given-names></name><name><surname>Cohen</surname><given-names>SL</given-names></name><name><surname>Cookingham</surname><given-names>J</given-names></name><name><surname>Coppa</surname><given-names>K</given-names></name><name><surname>Diefenbach</surname><given-names>MA</given-names></name><name><surname>Dominello</surname><given-names>AJ</given-names></name><name><surname>Duer-Hefele</surname><given-names>J</given-names></name><name><surname>Falzon</surname><given-names>L</given-names></name><name><surname>Gitlin</surname><given-names>J</given-names></name><name><surname>Hajizadeh</surname><given-names>N</given-names></name><name><surname>Harvin</surname><given-names>TG</given-names></name><name><surname>Hirschwerk</surname><given-names>DA</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Kozel</surname><given-names>ZM</given-names></name><name><surname>Marrast</surname><given-names>LM</given-names></name><name><surname>Mogavero</surname><given-names>JN</given-names></name><name><surname>Osorio</surname><given-names>GA</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Zanos</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area</article-title><source>JAMA</source><volume>323</volume><fpage>2052</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6775</pub-id><pub-id pub-id-type="pmid">32320003</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>J</given-names></name><name><surname>Barrera-Vilarmau</surname><given-names>S</given-names></name><name><surname>M C Teixeira</surname><given-names>J</given-names></name><name><surname>Sorokina</surname><given-names>M</given-names></name><name><surname>Seckel</surname><given-names>E</given-names></name><name><surname>Kastritis</surname><given-names>PL</given-names></name><name><surname>Levitt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Insights on cross-species transmission of SARS-CoV-2 from structural modeling</article-title><source>PLOoS Computational Biology</source><volume>16</volume><elocation-id>e1008449</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008449</pub-id><pub-id pub-id-type="pmid">33270653</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>C</given-names></name><name><surname>Schunk</surname><given-names>M</given-names></name><name><surname>Sothmann</surname><given-names>P</given-names></name><name><surname>Bretzel</surname><given-names>G</given-names></name><name><surname>Froeschl</surname><given-names>G</given-names></name><name><surname>Wallrauch</surname><given-names>C</given-names></name><name><surname>Zimmer</surname><given-names>T</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Janke</surname><given-names>C</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Vollmar</surname><given-names>P</given-names></name><name><surname>Zwirglmaier</surname><given-names>K</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>Wölfel</surname><given-names>R</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany</article-title><source>The New England Journal of Medicine</source><volume>382</volume><fpage>970</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001468</pub-id><pub-id pub-id-type="pmid">32003551</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Schrodinger</surname><given-names>LLC</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>The PyMOL Molecular Graphics System</data-title><publisher-name>Schrodinger LLC</publisher-name></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>McCauley</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GISAID: Global initiative on sharing all influenza data - from vision to reality</article-title><source>Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin</source><volume>22</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.13.30494</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkl</surname><given-names>P</given-names></name><name><surname>Watzenboeck</surname><given-names>ML</given-names></name><name><surname>Popov</surname><given-names>LM</given-names></name><name><surname>Zahalka</surname><given-names>S</given-names></name><name><surname>Hladik</surname><given-names>A</given-names></name><name><surname>Lakovits</surname><given-names>K</given-names></name><name><surname>Radhouani</surname><given-names>M</given-names></name><name><surname>Haschemi</surname><given-names>A</given-names></name><name><surname>Marichal</surname><given-names>T</given-names></name><name><surname>Reber</surname><given-names>LL</given-names></name><name><surname>Gaudenzio</surname><given-names>N</given-names></name><name><surname>Sibilano</surname><given-names>R</given-names></name><name><surname>Stulik</surname><given-names>L</given-names></name><name><surname>Fontaine</surname><given-names>F</given-names></name><name><surname>Mueller</surname><given-names>AC</given-names></name><name><surname>Amieva</surname><given-names>MR</given-names></name><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against <italic>Staphylococcus aureus</italic></article-title><source>Immunity</source><volume>53</volume><fpage>793</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.08.002</pub-id><pub-id pub-id-type="pmid">32910906</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungnak</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Bécavin</surname><given-names>C</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Queen</surname><given-names>R</given-names></name><name><surname>Litvinukova</surname><given-names>M</given-names></name><name><surname>Talavera-López</surname><given-names>C</given-names></name><name><surname>Maatz</surname><given-names>H</given-names></name><name><surname>Reichart</surname><given-names>D</given-names></name><name><surname>Sampaziotis</surname><given-names>F</given-names></name><name><surname>Worlock</surname><given-names>KB</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>JL</given-names></name><collab>HCA Lung Biological Network</collab></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nature Medicine</source><volume>26</volume><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0868-6</pub-id><pub-id pub-id-type="pmid">32327758</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swiecki</surname><given-names>M</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The multifaceted biology of plasmacytoid dendritic cells</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/nri3865</pub-id><pub-id pub-id-type="pmid">26160613</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Proteolytic activation of SARS-CoV-2 spike protein</article-title><source>Microbiology and Immunology</source><volume>66</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12945</pub-id><pub-id pub-id-type="pmid">34561887</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Wilkinson</surname><given-names>E</given-names></name><name><surname>Giovanetti</surname><given-names>M</given-names></name><name><surname>Iranzadeh</surname><given-names>A</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Giandhari</surname><given-names>J</given-names></name><name><surname>Doolabh</surname><given-names>D</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>San</surname><given-names>EJ</given-names></name><name><surname>Msomi</surname><given-names>N</given-names></name><name><surname>Mlisana</surname><given-names>K</given-names></name><name><surname>Gottberg</surname><given-names>A</given-names></name><name><surname>Walaza</surname><given-names>S</given-names></name><name><surname>Allam</surname><given-names>M</given-names></name><name><surname>Ismail</surname><given-names>A</given-names></name><name><surname>Mohale</surname><given-names>T</given-names></name><name><surname>Glass</surname><given-names>AJ</given-names></name><name><surname>Engelbrecht</surname><given-names>S</given-names></name><name><surname>Van Zyl</surname><given-names>G</given-names></name><name><surname>Oliveira</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emergence and Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with Multiple Spike Mutations in South Africa</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.21.20248640</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Tong</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and Its Receptor ACE2</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.02.14.431117</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turupcu</surname><given-names>A</given-names></name><name><surname>Oostenbrink</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Modeling of Oligosaccharides within Glycoproteins from Free-Energy Landscapes</article-title><source>Journal of Chemical Information and Modeling</source><volume>57</volume><fpage>2222</fpage><lpage>2236</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.7b00351</pub-id><pub-id pub-id-type="pmid">28816453</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaarala</surname><given-names>MH</given-names></name><name><surname>Porvari</surname><given-names>KS</given-names></name><name><surname>Kellokumpu</surname><given-names>S</given-names></name><name><surname>Kyllönen</surname><given-names>AP</given-names></name><name><surname>Vihko</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues</article-title><source>The Journal of Pathology</source><volume>193</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH743&gt;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">11169526</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Voloch</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.23.20248598</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>JQ</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>XX</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Geng</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>YM</given-names></name><name><surname>Nan</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>ZH</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Miao</surname><given-names>JL</given-names></name><name><surname>Cui</surname><given-names>HY</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>XM</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>CF</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>QY</given-names></name><name><surname>Bian</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>ZN</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells</article-title><source>Signal Transduction and Targeted Therapy</source><volume>5</volume><elocation-id>283</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-00426-x</pub-id><pub-id pub-id-type="pmid">33277466</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shuai</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Shan</surname><given-names>D</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Bu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice</article-title><source>Protein &amp; Cell</source><volume>11</volume><fpage>776</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1007/s13238-020-00767-x</pub-id><pub-id pub-id-type="pmid">32749592</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>A</given-names></name><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Tauriello</surname><given-names>G</given-names></name><name><surname>Gumienny</surname><given-names>R</given-names></name><name><surname>Heer</surname><given-names>FT</given-names></name><name><surname>de Beer</surname><given-names>TAP</given-names></name><name><surname>Rempfer</surname><given-names>C</given-names></name><name><surname>Bordoli</surname><given-names>L</given-names></name><name><surname>Lepore</surname><given-names>R</given-names></name><name><surname>Schwede</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SWISS-MODEL: homology modelling of protein structures and complexes</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W296</fpage><lpage>W303</lpage><pub-id pub-id-type="doi">10.1093/nar/gky427</pub-id><pub-id pub-id-type="pmid">29788355</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2021">2021a</year><article-title>Tracking SARS-CoV-2 variants</article-title><source>World Health Organisation</source><ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants</ext-link><date-in-citation iso-8601-date="2021-07-09">July 9, 2021</date-in-citation></element-citation></ref><ref id="bib73"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2021">2021b</year><article-title>WHO Coronavirus (COVID-19) Dashboard</article-title><source>World Health Organisation</source><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link><date-in-citation iso-8601-date="2021-07-09">July 9, 2021</date-in-citation></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Aw</surname><given-names>PPK</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Yeo</surname><given-names>GHT</given-names></name><name><surname>Ong</surname><given-names>SH</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Petric</surname><given-names>R</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>11189</fpage><lpage>11201</lpage><pub-id pub-id-type="doi">10.1093/nar/gks918</pub-id><pub-id pub-id-type="pmid">23066108</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>ES</given-names></name><name><surname>Bailey</surname><given-names>AL</given-names></name><name><surname>Kafai</surname><given-names>NM</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>McCune</surname><given-names>BT</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Earnest</surname><given-names>JT</given-names></name><name><surname>Keeler</surname><given-names>SP</given-names></name><name><surname>Ritter</surname><given-names>JH</given-names></name><name><surname>Kang</surname><given-names>LI</given-names></name><name><surname>Dort</surname><given-names>S</given-names></name><name><surname>Robichaud</surname><given-names>A</given-names></name><name><surname>Head</surname><given-names>R</given-names></name><name><surname>Holtzman</surname><given-names>MJ</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function</article-title><source>Nature Immunology</source><volume>21</volume><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0778-2</pub-id><pub-id pub-id-type="pmid">32839612</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><volume>367</volume><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmid">32132184</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>ML</given-names></name><name><surname>Teng</surname><given-names>JLL</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>J-P</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>K-H</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Siu</surname><given-names>K-L</given-names></name><name><surname>Fung</surname><given-names>S-Y</given-names></name><name><surname>Yung</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>TM</given-names></name><name><surname>To</surname><given-names>KK-W</given-names></name><name><surname>Chan</surname><given-names>JF-W</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>D-Y</given-names></name><name><surname>Woo</surname><given-names>PCY</given-names></name><name><surname>Yuen</surname><given-names>K-Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system</article-title><source>Cell</source><volume>184</volume><fpage>2212</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.053</pub-id><pub-id pub-id-type="pmid">33713620</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>CD</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Jackson</surname><given-names>AM</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Reincke</surname><given-names>SM</given-names></name><name><surname>Pruss</surname><given-names>H</given-names></name><name><surname>Kreye</surname><given-names>J</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants</article-title><source>Science</source><volume>10</volume><elocation-id>eabh1139</elocation-id><pub-id pub-id-type="doi">10.1126/science.abh1139</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Ginn</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Duyvesteyn</surname><given-names>HME</given-names></name><name><surname>Tuekprakhon</surname><given-names>A</given-names></name><name><surname>Nutalai</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><name><surname>Lopez-Camacho</surname><given-names>C</given-names></name><name><surname>Slon-Campos</surname><given-names>J</given-names></name><name><surname>Hallis</surname><given-names>B</given-names></name><name><surname>Coombes</surname><given-names>N</given-names></name><name><surname>Bewley</surname><given-names>K</given-names></name><name><surname>Charlton</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>TS</given-names></name><name><surname>Skelly</surname><given-names>D</given-names></name><name><surname>Lumley</surname><given-names>SF</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Crook</surname><given-names>D</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Clutterbuck</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>W</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Fry</surname><given-names>EE</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title><source>Cell</source><volume>184</volume><fpage>2348</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id><pub-id pub-id-type="pmid">33730597</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues</article-title><source>Cell</source><volume>181</volume><fpage>1016</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.035</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoufaly</surname><given-names>A</given-names></name><name><surname>Poglitsch</surname><given-names>M</given-names></name><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Hoepler</surname><given-names>W</given-names></name><name><surname>Seitz</surname><given-names>T</given-names></name><name><surname>Traugott</surname><given-names>M</given-names></name><name><surname>Grieb</surname><given-names>A</given-names></name><name><surname>Pawelka</surname><given-names>E</given-names></name><name><surname>Laferl</surname><given-names>H</given-names></name><name><surname>Wenisch</surname><given-names>C</given-names></name><name><surname>Neuhold</surname><given-names>S</given-names></name><name><surname>Haider</surname><given-names>D</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name><name><surname>Puchhammer-Stoeckl</surname><given-names>E</given-names></name><name><surname>Mirazimi</surname><given-names>A</given-names></name><name><surname>Montserrat</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human recombinant soluble ACE2 in severe COVID-19</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>1154</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30418-5</pub-id><pub-id pub-id-type="pmid">33131609</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74623.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.08.09.455606" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.09.455606"/></front-stub><body><p>To establish a mouse model for the SARS-CoV-2 infection, Gawish and colleagues performed serial passage of a human virus isolate in mice. They show that the mouse-adapted SARS-CoV-2 variant remains dependent on ACE2 for efficient infection, recapitulates some clinical characteristics of COVID-19, and acquired some changes also found in the Omicron variant of concern. Finally, the authors demonstrate that inhalation of recombinant ACE2 protected mice from mouse COVID-19, suggesting that this model will be useful for the testing of antiviral agents.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74623.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewer</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.09.455606">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.08.09.455606v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Frank Kirchhoff as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Infection is also dependent on proteolytic activation of the Spike protein by TMPRSS2 or Cathepsins. Please clarify whether any of the mutations in Spike affect potential cleavage sites and how conserved these proteases are between men and mice?</p><p>2. Mice show a drop in body temperature while humans develop fever. This difference should be explained for the non-expert. Similarly, the reasons for severe weight loss (loss of appetite, diarrhoea, other?) should briefly be mentioned.</p><p>3. The authors emphasize the similarities to human disease. They should also discuss differences; e.g. it seems that the incubation time is much shorter.</p><p>4. As mentioned by the authors, ACE2 is essential for infection and viral replication of mouse-adapted SARS-CoV-2 in mice. It seems more plausible to just show that ACE-KO mice are resistant to infection. If that is the case, it seems self-evident that they do not develop disease. Either a better rationale for studying clinical parameters in KO mice in the absence of infection should be provided or this part should be shortened substantially.</p><p>5. IFNs drive inflammation but also induce antiviral factors. Please clarify whether the induction of type I and II IFN responses associated with declines in viral loads?</p><p>6. It is stated that recombinant ACE2 was inhaled. This suggests that the protein was aerosolized and applied as spray. Add the respective description in the Materials and methods section.</p><p>7. &quot;albeit 1 x 105 (and higher) TCID50 induced a profound but transient body weight loss of about 15-20% (Figure 3D to F).&quot; Only panel D shows body weight and the loss loss seems generally &lt;20%. Clarify and revise.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Infection is also dependent on proteolytic activation of the Spike protein by TMPRSS2 or Cathepsins. Did any of the mutations in Spike affect potential cleavage sites and how conserved are these proteases between men and mice?</p><p>Mice show a drop in body temperature while humans develop fever. This difference should be explained for the non-expert. Similarly, the reasons for severe weight loss (loss of appetite, diarrhoea, other?) should briefly be mentioned.</p><p>The authors emphasize the similarities to human disease. They should also discuss differences; e.g. it seems that the incubation time is much shorter.</p><p>As mentioned by the authors, ACE2 is essential for infection and viral replication of mouse-adapted SARS-CoV-2 in mice. It seems more plausible to just show that ACE-KO mice are resistant to infection. If that is the case, it seems self-evident that they do not develop disease. Either a better rationale for studying clinical parameters in KO mice in the absence of infection should be provided or this part should be shortened substantially.</p><p>IFNs drive inflammation but also induce antiviral factors. Was the induction of type I and II IFN responses associated with declines in viral loads?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74623.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Infection is also dependent on proteolytic activation of the Spike protein by TMPRSS2 or Cathepsins. Please clarify whether any of the mutations in Spike affect potential cleavage sites and how conserved these proteases are between men and mice?</p></disp-quote><p>We thank the reviewer for highlighting this interesting and important aspect. Proteolytic processing of SARS-CoV-2 Spike at the S1/S2 (681-PRRAR; cleaved by furin) and the S2' (815-R; cleaved by TMPRSS2) cleavage sites is indeed important for infection. In the absence of furin and TMPRSS2, (less efficient) cathepsin L Spike processing at both sites has been suggested (Takeda, Microbiology and Immunology, 2021; PMID 34561887).</p><p>Of note, both cleavage sites are intact in maVie16.</p><p>Johnson, Xie et al., recently reported (Nature, 2021; PMID 33494095) that SARS-CoV-2 with a mutated S1/S2 cleavage site shows markedly decreased replication and pathogenicity in K18hACE2 mice (expressing human ACE2 under control of the K18 promoter), indicating that proteolytic (furin) cleavage is also an important factor in mouse models of COVID-19. This suggests that mice have the relevant proteases required for proteolytic SARS-CoV-2 processing. While the amino acid sequence similarity of furin is more than 90% between mouse and man, that of TMPRSS2 is approx. 80% (Vaarala et al., J. Pathol, 2001; PMID 11169526). Together we believe that the mutations in maVie16s Spike receptor binding domain (RBD) do not interfere with proteolytic processing and that original resistance of mice to infection with the human SARS-CoV-2 isolate Bav-Pat-1 is not due to differences in murine protease expression, but rather because the human virus cannot efficiently bind to mouse ACE2. We have now added the following paragraphs to our manuscript to address this issue:</p><p>“Since the observed Spike mutations are distant from putative cleavage sites (Takeda, 2021), it is likely that mACE2 affinity is increased without affecting proteolytic processing by proteases such as furin or TMPRSS2 (Takeda, 2021).” (page 6)</p><p>“At the same time, the multibasic S1/S2 furin cleavage site (681-PRRAR) as well as the S2’ cleavage site (at 815-R) were maintained, rendering maVie16 Spike accessible for proteolytic processing by endogenous proteases such as TMPRSS2 or furin, which are essential for productive infection (Takeda, 2021) and highly conserved between mice and men (Vaarala et al., 2001).” (page12)</p><disp-quote content-type="editor-comment"><p>2. Mice show a drop in body temperature while humans develop fever. This difference should be explained for the non-expert. Similarly, the reasons for severe weight loss (loss of appetite, diarrhoea, other?) should briefly be mentioned.</p></disp-quote><p>Thanks for bringing up these important points. We added a short comment to the Results section for clarification:</p><p>“Mice infected with passage 15 furthermore exhibited a severe drop in body temperature (Figure 1D), which is the regulatory response of mice to severe inflammation at room temperature (Garami et al., 2018).” (page 5)</p><p>While weight loss is a (the) major readout for systemic pathology in mouse models of viral infections, we can only speculate about the reason for the drop in bodyweight upon maVie16 infection. Previous studies revealed reduced food intake (anorexia) as the main reason for weight loss upon influenza infection in mice, whereas weight loss in other virus infections (e.g. lymphocytic choriomeningitis virus) was caused by a combination of anorexia and cachexia (Baazim et al., Nat Rev Immunology, 2021; PMID: 34608281). Notably, as we did not observe diarrhoea in infected mice, this can be excluded as potential explanation.</p><p>To address this issue in our manuscript, we added the following sentence (and a reference) to the Results section:</p><p>“a progressive loss of body weight of mice infected with later stage passaged SARS-CoV-2 indicated enhanced pathogenicity of the virus (Figure 1C). Weight loss is a sign of disease severity in many rodent models of infection, and related to anorexia and/or cachexia (Baazim et al., 2021).” (page 5)</p><disp-quote content-type="editor-comment"><p>3. The authors emphasize the similarities to human disease. They should also discuss differences; e.g. it seems that the incubation time is much shorter.</p></disp-quote><p>We thank the reviewer for this critical comment. While in humans, the typical incubation time between infection and symptom onset is around 4-5 days (Li, Guan, Wu, Wang, et al., NEJM, 2020; PMID: 31995857), maVie16-infected mice develop clinical signs of disease around day 2 post infection. One explanation for this difference might be the route of infection and the exposure dose. In mice, intranasal administration of maVie16 results in deep inhalation, and immediate exposure of the lower airways to virus. In contrast, humans usually get infected via droplets that first reach the upper airways (nasopharynx), where the virus replicates to then “move” down to the lower airways.</p><p>We have introduced a paragraph to highlight this difference in the discussion:</p><p>“The time to symptom onset was approximately 2-3 days, which is faster than reported in humans (around 5 days) (Li et al., 2020), and might be explained by the route of infection and subsequent high viral dose in the lower airways, as opposed to droplet infection of the upper respiratory tract in humans.” (page 12)</p><disp-quote content-type="editor-comment"><p>4. As mentioned by the authors, ACE2 is essential for infection and viral replication of mouse-adapted SARS-CoV-2 in mice. It seems more plausible to just show that ACE-KO mice are resistant to infection. If that is the case, it seems self-evident that they do not develop disease. Either a better rationale for studying clinical parameters in KO mice in the absence of infection should be provided or this part should be shortened substantially.</p></disp-quote><p>We fully agree that ACE2 deficiency likely renders mice resistant to infection and did not intend to speculate about other possibilities. Resistance to infection is also supported by our data showing a complete absence of nucleocapsid positive cells (Figure 7E) in lungs of infected Ace2<sup>-/y</sup> animals. We apologize for the confusion and have rephrased and shortened this part of our manuscript:</p><p>“In contrast to infected littermate control animals, Ace2<sup>-/y</sup> mice were fully protected against infection with 5 x 10<sup>5</sup> TCID50 maVie16, maintained stable body weight (Figure 7B) and temperature (Figure 7C) and were protected from pneumonia development as indicated by lower lung weight (Figure 7D) and the absence of any lung pathology (Figure 7E). Resistance to infection was further indicated by the complete absence of nucleocapsid-positive cells in lungs of Ace2<sup>-/y</sup> animals (Figure 7E). In conflict with this observation, we still detected similar viral genome copy numbers in both groups (Figure 7—figure supplement 1B), suggesting that this was reflective of initial maVie16 input rather than productive infection.” (page 10)</p><disp-quote content-type="editor-comment"><p>5. IFNs drive inflammation but also induce antiviral factors. Please clarify whether the induction of type I and II IFN responses associated with declines in viral loads?</p></disp-quote><p>We show that maVie16 induces a fast and robust plasmacytoid dendritic cell (pDC) response (Figure 4C), an important source of type I IFN, as well as expression of PKR (Figure 4D; eif2ak2), a typical antiviral factor induced by type I IFN, as early as 2 days post infection. This correlates with the peak of viral burden, which progressively declines from this point (Figure 5B). However, as others have shown that IFNs play an ambiguous role during COVID-19 and our study still lacks experiments with IFNAR1 deficient animals or type I IFN blocking antibodies, a causality between type I IFN and viral clearance in our modal cannot be claimed. In contrast to type I IFN, lung IFNγ levels peak on day 7 post infection, when lung pathology is most severe but maVie16 is already cleared (based on absence of nucleocapsid-positive lung cell). We conclude from our experiments using IFNγ blocking antibodies (Figure 6D-G and Figure 6—figure supplement 2) that type II IFN (in combination with TNF) rather contributes to immunopathology than to viral clearance in our model.</p><p>Immunopathologic features of type II IFN are already addressed in the Discussion section of our manuscript (page 12-13).</p><p>In addition, we have now added the following paragraph to further explain the role of type I IFN in our model:</p><p>“In addition, mCOVID-19 is characterized by an early pDC mobilization in blood and lung, associated with a fast pulmonary type I IFN response. This correlates with the peak of viral burden, which subsequently declines. However, as others have shown that IFNs play an ambiguous role during COVID-19 (Israelow et al., 2020), further experiments (e.g. using IFNAR1-deficient animals or type I IFN blocking antibodies) will be required to address the direct impact of type I IFNs on maVie16 clearance in vivo.” (page 12)</p><disp-quote content-type="editor-comment"><p>6. It is stated that recombinant ACE2 was inhaled. This suggests that the protein was aerosolized and applied as spray. Add the respective description in the Materials and methods section.</p></disp-quote><p>Thank you for this comment. We administered recombinant ACE2 via intranasal inhalation of anesthetized mice (which reduces the respiratory rate and ensures deep breaths, i.e. comparable to inhalation using asthma sprays), an established method to ensure application of compounds to the lower airways. To clarify this aspect, we added the following explanation to the methods section:</p><p>“Intranasal administration to anesthetized mice is an established method that allows administration of compounds to the lower airways via inhalation, due to the anesthesia-related low breathing rate and, hence, deep breaths” (page 25)</p><disp-quote content-type="editor-comment"><p>7. &quot;albeit 1 x 105 (and higher) TCID50 induced a profound but transient body weight loss of about 15-20% (Figure 3D to F).&quot; Only panel D shows body weight and the loss loss seems generally &lt;20%. Clarify and revise.</p></disp-quote><p>Thanks for bringing this to our attention. We originally decided to state 15-20% because as individual mice exhibited a weight loss decrease up to 19%. However, we realize that this is not clearly recognizable from the displayed mean value. To avoid confusion, we changed this statement to “15%” (page 7).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Infection is also dependent on proteolytic activation of the Spike protein by TMPRSS2 or Cathepsins. Did any of the mutations in Spike affect potential cleavage sites and how conserved are these proteases between men and mice?</p></disp-quote><p>We thank the reviewer for highlighting this interesting and important aspect. Proteolytic processing of SARS-CoV-2 Spike at the S1/S2 (681-PRRAR; cleaved by furin) and the S2' (815-R; cleaved by TMPRSS2) cleavage sites is indeed important for infection. In the absence of furin and TMPRSS2, (less efficient) cathepsin L Spike processing at both sites has been suggested (Takeda, Microbiology and Immunology, 2021; PMID 34561887).</p><p>Of note, both cleavage sites are intact in maVie16.</p><p>Johnson, Xie et al., recently reported (Nature, 2021; PMID 33494095) that SARS-CoV-2 with a mutated S1/S2 cleavage site shows markedly decreased replication and pathogenicity in K18hACE2 mice (expressing human ACE2 under control of the K18 promoter), indicating that proteolytic (furin) cleavage is also an important factor in mouse models of COVID-19. This suggests that mice have the relevant proteases required for proteolytic SARS-CoV-2 processing. While the amino acid sequence similarity of furin is more than 90% between mouse and man, that of TMPRSS2 is approx. 80% (Vaarala et al., J. Pathol, 2001; PMID 11169526). Together we believe that the mutations in maVie16s Spike receptor binding domain (RBD) do not interfere with proteolytic processing and that original resistance of mice to infection with the human SARS-CoV-2 isolate Bav-Pat-1 is not due to differences in murine protease expression, but rather because the human virus cannot efficiently bind to mouse ACE2. We have now added the following paragraphs to our manuscript to address this issue:</p><p>“Since the observed Spike mutations are distant from putative cleavage sites (Takeda, 2021), it is likely that mACE2 affinity is increased without affecting proteolytic processing by proteases such as furin or TMPRSS2 (Takeda, 2021).” (page 6)</p><p>“At the same time, the multibasic S1/S2 furin cleavage site (681-PRRAR) as well as the S2’ cleavage site (at 815-R) were maintained, rendering maVie16 Spike accessible for proteolytic processing by endogenous proteases such as TMPRSS2 or furin, which are essential for productive infection (Takeda, 2021) and highly conserved between mice and men (Vaarala et al., 2001).” (page12)</p><disp-quote content-type="editor-comment"><p>Mice show a drop in body temperature while humans develop fever. This difference should be explained for the non-expert. Similarly, the reasons for severe weight loss (loss of appetite, diarrhoea, other?) should briefly be mentioned.</p></disp-quote><p>Thanks for bringing up these important points. We added a short comment to the Results section for clarification: „Mice infected with passage 15 furthermore exhibited a severe drop in body temperature (Figure 1D), which is the regulatory response of mice to severe inflammation at room temperature (Garami et al., 2018).” (page 5)</p><p>While weight loss is a (the) major readout for systemic pathology in mouse models of viral infections, we can only speculate about the reason for the drop in bodyweight upon maVie16 infection. Previous studies revealed reduced food intake (anorexia) as the main reason for weight loss upon influenza infection in mice, whereas weight loss in other virus infections (e.g. lymphocytic choriomeningitis virus) was caused by a combination of anorexia and cachexia (Baazim et al., Nat Rev Immunology, 2021; PMID: 34608281). Notably, as we did not observe diarrhea in infected mice, this can be excluded as potential explanation.</p><p>To address this issue in our manuscript, we added the following sentence (and a reference) to the Results section:</p><p>“a progressive loss of body weight of mice infected with later stage passaged SARS-CoV-2 indicated enhanced pathogenicity of the virus (Figure 1C). Weight loss is a sign of disease severity in many rodent models of infection, and related to anorexia and/or cachexia (Baazim et al., 2021).” (page 5)</p><disp-quote content-type="editor-comment"><p>The authors emphasize the similarities to human disease. They should also discuss differences; e.g. it seems that the incubation time is much shorter.</p></disp-quote><p>We thank the reviewer for this critical comment. While in humans, the typical incubation time between infection and symptom onset is around 4-5 days (Li, Guan, Wu, Wang, et al., NEJM, 2020; PMID: 31995857), maVie16-infected mice develop clinical signs of disease around day 2 post infection. One explanation for this difference might be the route of infection and the exposure dose. In mice, intranasal administration of maVie16 results in deep inhalation, and immediate exposure of the lower airways to virus. In contrast, humans usually get infected via droplets that first reach the upper airways (nasopharynx), where the virus replicates to then “move” down to the lower airways.</p><p>We have introduced a paragraph to highlight this difference in the discussion:</p><p>“The time to symptom onset was approximately 2-3 days, which is faster than reported in humans (around 5 days) (Li et al., 2020), and might be explained by the route of infection and subsequent high viral dose in the lower airways, as opposed to droplet infection of the upper respiratory tract in humans.” (page 12)</p><disp-quote content-type="editor-comment"><p>As mentioned by the authors, ACE2 is essential for infection and viral replication of mouse-adapted SARS-CoV-2 in mice. It seems more plausible to just show that ACE-KO mice are resistant to infection. If that is the case, it seems self-evident that they do not develop disease. Either a better rationale for studying clinical parameters in KO mice in the absence of infection should be provided or this part should be shortened substantially.</p></disp-quote><p>We fully agree that ACE2 deficiency likely renders mice resistant to infection and did not intend to speculate about other possibilities. Resistance to infection is also supported by our data showing a complete absence of nucleocapsid positive cells (Figure 7E) in lungs of infected Ace2<sup>-/y</sup> animals. We apologize for the confusion and have rephrased and shortened this part of our manuscript:</p><p>“In contrast to infected littermate control animals, Ace2<sup>-/y</sup> mice were fully protected against infection with 5 x 10<sup>5</sup> TCID50 maVie16, maintained stable body weight (Figure 7B) and temperature (Figure 7C) and were protected from pneumonia development as indicated by lower lung weight (Figure 7D) and the absence of any lung pathology (Figure 7E). Resistance to infection was further indicated by the complete absence of nucleocapsid-positive cells in lungs of Ace2<sup>-/y</sup> animals (Figure 7E). In conflict with the absence of nucleocapsid-positive cells, we still detected similar viral genome copy numbers in both groups (Figure 7—figure supplement 1B), suggesting that this was reflective of initial maVie16 input rather than productive infection.” (page 10)</p><disp-quote content-type="editor-comment"><p>IFNs drive inflammation but also induce antiviral factors. Was the induction of type I and II IFN responses associated with declines in viral loads?</p></disp-quote><p>We show that maVie16 induces a fast and robust plasmacytoid dendritic cell (pDC) response (Figure 4C), an important source of type I IFN, as well as expression of PKR (Figure 4D; eif2ak2), a typical antiviral factor induced by type I IFN, as early as 2 days post infection. This correlates with the peak of viral burden, which progressively declines from this point (Figure 5B). However, as others have shown that IFNs play an ambiguous role during COVID-19 and our study still lacks experiments with IFNAR1 deficient animals or type I IFN blocking antibodies, a causality between type I IFN and viral clearance in our modal cannot be claimed. In contrast to type I IFN, lung IFNγ levels peak on day 7 post infection, when lung pathology is most severe but maVie16 is already cleared (based on absence of nucleocapsid-positive lung cell). We conclude from our experiments using IFNγ blocking antibodies (Figure 6D-G and Figure 6—figure supplement 2) that type II IFN (in combination with TNF) rather contributes to immunopathology than to viral clearance in our model.</p><p>Immunopathologic features of type II IFN are already addressed in the Discussion section of our manuscript (page 12-13).</p><p>In addition, we have now added the following paragraph to further explain the role of type I IFN in our model:</p><p>“In addition, mCOVID-19 is characterized by an early pDC mobilization in blood and lung, associated with a fast pulmonary type I IFN response. This correlates with the peak of viral burden, which subsequently declines. However, as others have shown that IFNs play an ambiguous role during COVID-19 (Israelow et al., 2020), further experiments (e.g. using IFNAR1-deficient animals or type I IFN blocking antibodies) will be required to address the direct impact of type I IFNs on maVie16 clearance in vivo.” (page 12)</p><p>References</p><p>Dinnon, K. H., 3rd, Leist, S. R., Schafer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Jr., Hou, Y. J., Adams, L. E., Gully, K. L., Brown, A. J., Huang, E., Bryant, M. D., Choong, I. C., Glenn, J. S., Gralinski, L. E., Sheahan, T. P., and Baric, R. S. (2020). A mouseadapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 586(7830), 560566. https://doi.org/10.1038/s41586-020-2708-8</p><p>Huang, K., Zhang, Y., Hui, X., Zhao, Y., Gong, W., Wang, T., Zhang, S., Yang, Y., Deng, F., Zhang, Q., Chen, X., Yang, Y., Sun, X., Chen, H., Tao, Y. J., Zou, Z., and Jin, M. (2021). Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine, 67, 103381. https://doi.org/10.1016/j.ebiom.2021.103381</p><p>Leist, S. R., Dinnon, K. H., 3rd, Schafer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., Gully, K. L., Scobey, T., Brown, A. J., Sheahan, T. P., Moorman, N. J., Boucher, R. C., Gralinski, L. E., Montgomery, S. A., and Baric, R. S. (2020). A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 183(4), 1070-1085 e1012. https://doi.org/10.1016/j.cell.2020.09.050</p><p>Takeda, M. (2021). Proteolytic activation of SARS-CoV-2 spike protein. Microbiol Immunol. https://doi.org/10.1111/1348-0421.12945</p><p>Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G.,. de Oliveira, T. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARSCoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020.2012.2021.20248640. https://doi.org/10.1101/2020.12.21.20248640</p><p>Vaarala, M. H., Porvari, K. S., Kellokumpu, S., Kyllonen, A. P., and Vihko, P. T. (2001). Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol, 193(1), 134-140. https://doi.org/10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH743&gt;3.0.CO;2-T</p><p>Voloch, C. M., Silva F, R. d., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. d. C., Mariani, D., Costa, R. M. d., Ferreira, O. C., Cavalcanti, A. C., Frauches, T. S., de Mello, C. M. B., Galliez, R. M., Faffe, D. S., Castiñeiras, T. M. P. P., Tanuri, A., and de Vasconcelos, A. T. R. (2020). Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv, 2020.2012.2023.20248598. https://doi.org/10.1101/2020.12.23.20248598</p><p>Wang, J., Shuai, L., Wang, C., Liu, R., He, X., Zhang, X., Sun, Z., Shan, D., Ge, J., Wang, X., Hua, R., Zhong, G., Wen, Z., and Bu, Z. (2020). Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell, 11(10), 776-782. https://doi.org/10.1007/s13238-020-00767-x</p></body></sub-article></article>